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ABSTRACT 
Patients with hematological malignancies are at high risk for severe infections such 
as bacteremia, pneumonia, and meningitis caused by Streptococcus pneumoniae (invasive 
pneumococcal disease (IPD)). IPD is related to marked morbidity and mortality in 
these patients. However, only limited population-based data is available concerning 
IPD in patients with hematological malignancies.  
Pneumococcal vaccines currently in use have restricted efficacy against IPD in 
patients with hematological malignancies. In patients with chronic lymphocytic 
leukemia (CLL, a malignancy of mature B-lymphocytes), pneumococcal 
polysaccharide vaccines have so far been inefficient. In comparison, T-cell 
dependent conjugate vaccines are more immunogenic and are capable of inducing 
immunologic memory. It has been shown that some CLL patients achieve protective 
antibody responses against IPD with conjugate vaccines.  
The aims of this thesis were to evaluate the incidence of IPD, the serotype 
distribution of the isolated strains, and serotype coverage of pneumococcal vaccines 
in Finnish patients with specific hematological malignancies. In CLL patients, the 
main objectives were to assess the antibody persistence after five years of the 
administration of 7-valent pneumococcal conjugate vaccine and the efficacy of the 
23-valent pneumococcal polysaccharide vaccine booster dose given five years after 
the conjugate vaccine. Furthermore, the activation and expression of indoleamine 
2,3-dioxygenase (IDO), which suppresses T-cell functions by catalyzing tryptophan 
metabolism, was evaluated, including its possible effects on antibody response to 7-
valent pneumococcal conjugate vaccine. 
The overall incidence rate of IPD among patients with hematological 
malignancies was 3.8 per 1000 person-years within one year of a diagnosis of 
hematological malignancy. The highest rate of IPD was in patients with multiple 
myeloma. The risk of IPD in patients with multiple myeloma was 2.7 to 12 times 
higher compared to other hematological malignancies. The most common serotypes 
causing IPD were 14 and 6B. The serotype distribution was, to some extent, different 
from the general adult population. In CLL patients, 57% and 64% of isolates were 
covered by 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal 
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polysaccharide vaccine, respectively, while 32% of isolates were covered by neither 
of these vaccines. 
The antibody concentrations in 24 CLL patients and 8 controls five years after 
the administration of 7-valent pneumococcal conjugate vaccine did not differ 
statistically. A trend toward lower concentrations was seen in CLL patients for six 
serotypes compared to controls. In CLL patients, median antibody concentrations 
declined almost 50% for four serotypes over the course of five years following the 
administration of 7-valent pneumococcal conjugate vaccine. 
Only 10 to 15% of the CLL patients achieved a significant response to 
pneumococcal antigens included in 7-valent pneumococcal conjugate vaccine one 
month after the administration of 23-valent pneumococcal polysaccharide booster 
vaccine defined as an at least two-fold increase and a post-vaccination concentration 
of at least 0.35 µg/ml. Antibody concentrations were significantly higher in controls 
for four antigens included in the conjugate vaccine and for both measured antigens 
in the polysaccharide vaccine. 
IDO activity and expression was assessed in 49 CLL patients and 24 controls. 
IDO activity was significantly higher in patients with CLL. In contrast, IDO 
expression in peripheral blood mononuclear cells representing malignant B-cells was 
significantly reduced. Thus, these findings suggest that increased IDO activation is 
derived from cells other than malignant B-cells. Increased IDO activity did not have 
an effect on vaccine responses. 
In conclusion, serotype coverage of pneumococcal vaccines in patients with 
hematological malignancies seems to be lower compared to general population. In 
patients with CLL, pneumococcal conjugate vaccine given at an early stage of the 
disease seems to induce an antibody response lasting at least five years. However, 
pneumococcal conjugate vaccine is not capable of inducing properly functional 
memory B-cells in CLL patients. Hence, 23-valent pneumococcal polysaccharide 
vaccine given after conjugate vaccine does not seem to bring any benefits in 
vaccination strategies in patients with CLL. 
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TIIVISTELMÄ 
Hematologista maligniteettia sairastavien potilaiden riski sairastua Streptococcus 
pneumoniaen aiheuttamiin vakaviin invasiivisiin pneumokokki-infektioihin (IPI) on 
suuri. Näitä infektioita ovat sepsis, keuhkokuume ja aivokalvontulehdus. IPI:in liittyy 
tässä korkean riskin potilasryhmässä huomattava sairastavuus ja kuolleisuus. 
Hematologista maligniteettia sairastavien potilaiden IPI:a koskevaa väestöpohjaista 
tutkimustietoa on vähän. 
Nykyään käytettävien pneumokokkirokotteiden teho IPI:a vastaan hematologista 
maligniteettia sairastavilla on alentunut. Kroonista lymfaattista leukemiaa (KLL, 
kypsien B-lymfosyyttien pahanlaatuinen tauti) sairastavilla potilailla 
pneumokokkipolysakkaridirokotteet ovat toistaiseksi osoittautuneet tehottomiksi. T-
soluista riippuvaiset konjugaattirokotteet ovat immunogeeniselta teholtaan parempia 
ja pystyvät muodostamaan immunologisen muistin. Osalle KLL-potilaista 
konjugaattirokotteet tuottavat suojaavan vasta-ainevasteen IPI:a vastaan. 
Väitöskirjatyön tavoitteena oli arvioida suomalaisilla hematologista maligniteettia 
sairastavilla potilailla IPI:n ilmaantuvuutta ja serotyyppijakaumaa sekä 
pneumokokkirokotteiden serotyyppikattavuutta. KLL-potilailla tavoitteena oli 
selvittää pneumokokkivasta-aineiden säilymistä seitsemän serotyypin 
konjugaattirokotuksen jälkeen sekä arvioida 23 serotyypin polysakkaridirokotteen 
tehoa, kun tehosteannos annettiin viiden vuoden kuluttua konjugaattirokotteesta. 
Lisäksi selvitettiin tryptofaania katalysoivan ja T-solujen toimintaa heikentävän 
indoleamiini 2,3-dioksigenaasi -entsyymin (IDO) aktivaatiota ja ekspressiota sekä sen 
mahdollista vaikutusta seitsemän serotyypin konjugaattirokotteen rokotevasteeseen 
KLL-potilailla. 
IPI:n ilmaantuvuus yhden vuoden kuluessa hematologisen maligniteetin 
diagnoosista oli 3.8 per 1000 henkilövuotta. Suurin ilmaantuvuus oli multippelia 
myeloomaa sairastavilla potilailla, joiden riski sairastua IPI:iin oli 2.7-12 kertainen 
muihin hematologisiin maligniteetteihin verrattuna. Yleisimmät IPI-tapausten 
pneumokokkiserotyypit olivat 14 ja 6B. Serotyyppien jakauma erosi hieman muun 
aikuisväestön serotyyppijakaumasta. Kolmentoista serotyypin konjugaattirokote 
kattoi 57% IPI:n aiheuttaneista kannoista ja 23 serotyypin polysakkaridirokote 64%. 
Kumpikaan rokote ei kattanut 32 % kannoista. 
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Viiden vuoden kuluttua seitsemän serotyypin konjugaattirokotuksesta ei todettu 
tilastollisesti merkittävää eroa 24 KLL-potilaan ja kahdeksan verrokkipotilaan 
pneumokokkivasta-ainepitoisuuksissa. Kuutta serotyyppiä kohtaan vasta-
ainepitoisuudet olivat KLL-potilailla matalampia kuin verrokkipotilailla. Näistä 
neljää serotyyppiä kohtaan vasta-ainepitoisuudet laskivat lähes 50%. 
Kahdenkymmenenkolmen serotyypin polysakkariditehosterokotteella vain 10-
15% KLL-potilaista sai merkittävän rokotevasteen seitsemän serotyypin 
konjugaattirokotteen sisältämiä serotyyppejä kohtaan. Verrokkipotilaiden vasta-
ainepitoisuudet olivat merkitsevästi korkeampia neljälle konjugaattirokotteen ja 
kahdelle mitatulle polysakkaridirokotteen sisältämille serotyypeille. 
IDO:n aktiivisuus ja ekspressio määritettiin 49 KLL-potilaalta ja 24 verrokilta. 
KLL-potilaiden IDO:n aktiivisuus oli merkitsevästi korkeampi kuin verrokeilla. 
IDO:n ekspressio pahanlaatuisia B-soluja edustavissa veren mononukleaarisissa 
soluissa oli KLL-potilailla kuitenkin merkitsevästi alentunut. Tämä viittaa siihen, että 
KLL-potilaiden suurentunut IDO:n aktiivisuus on peräisin muista soluista kuin 
pahanlaatuisista B-soluista. Rokotevasteisiin lisääntyneellä IDO:n aktiivisuudella ei 
havaittu olevan vaikutusta. 
Yhteenvetona, pneumokokkirokotteiden serotyyppikattavuus hematologista 
maligniteettia sairastavilla potilailla vaikuttaa olevan matalampi kuin muulla väestöllä. 
Pneumokokkikonjugaattirokotteen avulla suojaavan rokotusvasteen invasiivista 
pneumokokki-infektiota vastaan saaneiden KLL-potilaiden vasta-aineiden todettiin 
säilyvän vähintään viiden vuoden ajan. KLL-potilaat eivät kuitenkaan pysty 
muodostamaan normaalisti toimivia muisti B-soluja konjugaattirokotteen turvin. 
Näin ollen 23 serotyypin pneumokokkipolysakkariditehosterokote ei ole hyödyllinen 
osana KLL-potilaiden rokotusohjelmaa. 
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1 INTRODUCTION 
Invasive pneumococcal disease (IPD) is caused by Gram-positive bacteria 
Streptococcus pneumoniae spreading to normally sterile sites leading to bacteremia, 
pneumonia, or meningitis (Drijkoningen & Rohde 2014). Immunocompromised 
persons, such as patients with hematological malignancies are at the highest risk for 
IPD (Kyaw et al. 2005). Only limited population-based data are available concerning 
IPD in these patients. In a previous study, adults with hematological malignancies 
had a 50 times higher risk for IPD compared to the general population (Klemets et 
al. 2008).  
Chronic lymphocytic leukemia (CLL) is a malignancy of mature B-cell 
lymphocytes. CLL is the most common type of leukemia in adult Caucasians 
(Chiorazzi et al. 2005). Infections are the most common cause of mortality in CLL 
patients. The majority of infections are caused by common bacterial pathogens, 
including Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae 
(Morrison 2010). Patients with CLL have significant dysfunctions of the immune 
system predisposing to severe infections, particularly in the advanced stage of the 
disease (Dearden 2008; Forconi & Moss 2015). 
Antibody response particularly to pneumococcal polysaccharide vaccines (PPVs) 
has been poor in patients with CLL and other hematological malignancies 
(Hartkamp et al. 2001; Hinge et al. 2012; Sinisalo et al. 2001). Pneumococcal 
conjugate vaccines (PCVs) have been shown to induce better, albeit still limited, 
antibody responses in these patients (Cordonnier et al 2009; Sinisalo et al. 2007; 
Svensson et al. 2018).  
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes the degradation 
of tryptophan (trp) into kynurenine (kyn). IDO suppresses T-cell proliferation and 
activation by reducing trp concentration in tissues contributing to immunotolerance 
and immunosuppression (Mellor & Munn 1999). Overexpression of IDO has been 
shown in many malignant diseases in which it diminishes the response of the 
immune system against the tumor cells (Munn & Mellor 2016). 
The aim of this thesis was to distinguish features of IPD in patients with 
hematological malignancies and evaluate serotype coverage of pneumococcal 
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vaccines. In CLL patients, antibody persistence after PCV and the efficacy of the 
PPV booster after PCV were assessed. Furthermore, IDO activation and expression 
and the possible effect on vaccine response were determined. 
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2 REVIEW OF THE LITERATURE 
2.1 Invasive pneumococcal disease (IPD) 
2.1.1 Streptococcus pneumoniae 
Streptococcus pneumoniae is a Gram-positive bacteria, the virulence of which is mainly 
derived from external polysaccharide capsules and cholesterol-dependent toxin 
pneumolysin (Briles et al. 1992; Hyams et al. 2010; Kadioglu et al. 2008). Today, 
almost 100 distinct capsular types (serotypes) have been described (Geno et al. 2015). 
S.pneumoniae serotypes can cause asymptomatic colonization in nasopharynx of about 
5% of adults over 50 years of age (Le Polain de Waroux et al. 2014). When spreading 
from the nasopharynx, serotypes can cause mucosal infections like otitis, sinusitis, 
and bronchitis (Sorensen & Edgar, 2018). Only 20 to 30 serotypes can produce 
significant pneumococcal infection (Geno et al. 2015). 
2.1.2 Definition and epidemiology 
When S.pneumoniae serotypes invade normally sterile sites they can cause bacteremia, 
pneumonia, and meningitis. These are defined as invasive pneumococcal disease 
(IPD) (Bogaert et al. 2004). Globally IPD has a major impact on morbidity and 
mortality (Drijkoningen and Rohde 2014; Verhaegen et al. 2014). Incidence of IPD 
is influenced by e.g. age, socioeconomic factors, and comorbidities (Chapman et al. 
2013; Klemets et al. 2008; Reinert et al. 2005). Depending on the age, young children 
and older adults are at the highest risk for IPD (Pérez-Trallero et al. 2009; Harboe 
et al. 2010). During the 1980s and 1990s, before the introduction of 7-valent 
pneumococcal conjugate vaccine (PCV7) to the childhood vaccination program, the 
median incidence of IPD in Denmark was 15.7 per 100 000 (Harboe et al. 2010). 
After the introduction of pneumococcal conjugate vaccines (PCVs), the incidence 
of IPD has mainly declined due to indirect herd immunity (Rashid et al. 2012). After 
3 years of childhood PCV vaccination program in Denmark, the overall incidence 
20 
rate of IPD decreased significantly from 19.5 to 17.7 per 100 000. A corresponding 
decrease in IPD incidence in adults 65 years of age and older was from 65.5 to 59.7 
per 100 000 (Ingels et al. 2012). In the United States, the incidence rate of IPD in 
adults 50 years of age and older declined from 40.8 cases/100 000 in 1998-1999 to 
29.4/100 000 in 2002-2003, i.e. 28% (Lexau et al. 2005). In Finland, the use of 10-
valent pneumococcal conjugate vaccine (PCV10) in infant vaccination program 
decreased pneumonia hospitalizations by 6.7% in persons aged over 65 years 
(Okasha et al. 2018). A corresponding decline in IPD incidence has been reported 
also with the use of 13-valent pneumococcal conjugate vaccine (PCV13) (Camara et 
al. 2017; Harboe et al. 2014; Moore et al. 2015). Although the incidence of IPD in 
adults 65 years of age and older has declined since the introduction of PCV13, it still 
remains high (Harboe et al. 2014). A reduction in the IPD incidence has usually been 
seen for those serotypes which are included in conjugate vaccines whereas the 
incidence rate due to non-vaccine serotypes (NVTs) has increased. This 
phenomenon is called serotype replacement (van der Linden et al. 2015). Contrary, 
in Ireland the overall incidence rate of IPD in adults has not changed, but the 
incidence rate due to PCV serotypes has also declined (Corcoran et al. 2017). 
Furthermore, in Sweden in adults over 65 years of age, the proportion of NVTs 
increased after the introduction of PCVs, and they now account for 72% of IPD 
cases (Naucler et al. 2017). Recent analysis from 10 European countries consistently 
revealed that the incidence rates of IPD caused by PCV serotypes declined in adults 
over 65 years of age by more than 70% over a 5 year period of childhood vaccination 
programs with PCV10 or PCV13. An increase in NVTs only accounted for 9% of 
the overall decline (Hanquet et al. 2018). 
The serotype distribution in IPD has changed over the decades. In Denmark, 
before the introduction of PCV7, the proportion of serotypes 4, 9, and 19A 
increased, proportion of serotype 18C decreased, and serotype 2 almost disappeared 
(Harboe et al. 2010). During the first 3 years of the PCV7 vaccination program in 
the overall Danish population, the proportions of NVTs 7F and 19A increased 
significantly (Ingels et al. 2012). The proportion of serotype 19A also increased 
during the first 2 years after the introduction of PCV13 in adults 65 years of age and 
older (Harboe et al. 2014). 
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2.1.3 IPD in hematological malignancies 
2.1.3.1 Incidence and risk 
Patients with hematological malignancies are at the highest risk of IPD (Breiman et 
al. 1997; Kyaw et al. 2005). The epidemiologic data on IPD in specific hematological 
malignancies are still quite limited. In two surveillance programs in the United States, 
the incidence rate of IPD in adults with hematologic cancer was 503 per 100 000 
persons, which was the highest in adults with chronic illnesses (Kyaw et al. 2005). A 
comparable risk was found in the Finnish population where the incidence rate of 
IPD in patients with hematological malignancies was 547 per 100 000 persons, which 
was higher than in other immunocompromising conditions (Klemets et al. 2008). 
The risk of IPD is estimated to be highest in patients with multiple myeloma, a 
malignancy of plasma cells (Mufson et al. 2012; Savage et al. 1982; Wong et al. 2010). 
The risk of IPD in myeloma patients in the Canadian province of Alberta from 2000 
to 2004 was over 60 times higher than in the general population (Wong et al. 2010). 
The risk was even higher in the Gothenburg region in Sweden between 1996 and 
2008 where myeloma patients had 154 times higher risk for IPD than persons 
without myeloma (Backhaus et al. 2016). 
There are only few studies available concerning incidence rates of IPD in patients 
with CLL. A study from Alberta revealed an incidence rate of 124 per 100 000 
patients, which led to 12.6-fold risk for IPD in patients with CLL compared to the 
general population (Wong et al. 2010). A higher incidence rate was found in the 
Gothenburg area in Sweden, where the rate was 429 per 100 000 patients. The risk 
for IPD was 29-fold compared with persons without CLL (Backhaus et al. 2016). 
The data from patients with acute leukemia are even more limited. In a study of 
a pediatric acute lymphoblastic leukemia (ALL) population, the risk for IPD varied 
between age groups from 7.6 to 50.6 -fold compared with the general population 
(Meisel et al. 2007). In Alberta, the incidence rate of IPD in adults 18 years of age 
and older with acute myeloid or lymphoblastic leukemia was 129 per 100 000 
patients. The risk for IPD was 11.9-fold compared to the general population (Wong 
et al. 2010). 
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2.1.3.2 Serotype distribution 
In a study with adult patients suffering from hematological malignancies and lung 
cancer, the only serotype with an increased prevalence compared to the general adult 
population was serotype 6A (Wong et al. 2010). This serotype was independently 
related to hematological malignancies in a study with immunocompromised adults. 
Serotypes 10A, 11A, 23F, and 33F were also more frequently found in the study 
population on the whole (Luján et al. 2013).  In a retrospective study in two French 
hematology departments, the most frequent serotypes were 9V and 19F, but only 25 
IPD episodes were observed (Debbache et al. 2009). In the European Society for 
Blood and Marrow Transplantation (EBMT) survey, the serotypes identified in 51 
IPD episodes after hematopoietic stem cell transplantation (HSCT), were 6, 9, 11, 
14, 22, and 23F, but only 33% of the episodes were serotyped (Engelhard et al. 2002). 
Serotype replacement in patients with hematological malignancy after the 
introduction of PCVs has not been studied. However, rates of IPD among adults 
with HIV (human immunodeficiency virus), who represent another important group 
of immunocompromised persons, non-PCV7 serotypes increased 60% during the 7 
years after PCV7 introduction (Cohen et al. 2010). 
2.2 Chronic lymphocytic leukemia (CLL) 
2.2.1 Background 
CLL is a malignancy of mature B lymphocytes (Chiorazzi et al. 2005). It is 
characterized by an expansion of clonal B lymphocytes which proliferates in the 
bone marrow, peripheral blood, lymph nodes, and spleen. CLL is the most common 
type of adult leukemia in Caucasians, accounting for almost 40% of leukemias (Linet 
et al. 2007). The count of peripheral blood B lymphocytes ≥5 x 109/l, lasting for at 
least 3 months, is required for diagnosis of CLL. Diagnosis is confirmed from 
peripheral blood by flow cytometry, evincing clonality of B lymphocytes expressing 
either κ or λ immunoglobulin light chains. Furthermore, the typical 
immunophenotypic features of CLL include the expression of CD19, CD5, CD20, 
and CD23 expressions (Rawstron et al. 2018). 
During the normal maturation, B lymphocytes undergo rearrangement of 
immunoglobulin (Ig) variable (V) genes. This rearrangement encompasses mutations 
in VHDJH and VLJL gene segments (Chiorazzi et al. 2005). On the basis of the heavy 
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chain variable region gene mutations, CLL is divided into two groups: one where 
CLL cells have rearranged VH genes (“mutated” CLL; IGHV-M) and the other one 
with few or no mutations at all (“unmutated” CLL) (Hashimoto et al. 1995). The 
unmutated IGHV mutation status has been shown to associate with shorter survival 
(Hamblin et al. 1999). 
Signaling through B-cell receptor (BCR) plays a critical role in the survival and 
proliferation of CLL clones. Stimulation of BCR by antigen engagement induces 
activation of downstream kinases spleen tyrosine kinase (Syk), Bruton’s tyrosine 
kinase (Btk), and phosphatidylinositol-3 kinases (PI3Ks) (Herman et al. 2011; 
Quiroga et al. 2009; Ringshausen et al. 2002). Furthermore, interactions between 
CLL cells and the bone marrow and/or lymphoid tissue microenvironment are in 
the key role, promoting the growth and prevention of apoptosis in CLL cells. The 
most important factors in the CLL microenvironment are monocyte-derived nurse-
like cells (NLCs), mesenchymal stromal cells, follicular dendritic cells (DC), 
endothelial cells, and T-cells (Burger et al. 2009; Ten Hacken & Burger 2016). 
2.2.2 Genetic lesions in CLL  
CLL is divided into three risk groups based on the fluorescence in situ hybridization 
(FISH) model: high-risk, intermediate-risk and low-risk CLL. The most frequent 
genetic lesion found in 50-60% of CLL cases is deletions of the 13q14 region. 
Del13q14 is more frequently associated with IGHV-M CLL and is usually the only 
cytogenetic abnormality detected. Patients with del13q14 tend to have favorable 
prognosis and are categorized as low-risk patients (Dohner et al. 2000). 
Trisomy 12, an extra copy of chromosome 12, is found in almost 15% of CLL 
patients. It has been categorized as intermediate-risk CLL in the past. An unfavorable 
prognosis is attached to patients with deletions in the 11q22-23 chromosomal region 
or in the 17p13 region and a mutationally inactivated tumor suppressor gene TP53. 
11q deletions are found in almost 20% of advanced stage CLL patients and are 
frequently connected to the inactivation of the tumor suppressor gene ataxia 
telangiectasia mutated (ATM) and IGHV-UM CLL type. Marked lymphadenopathy 
is a common clinical feature of patients with 11q deletions. 17p deletions and TP53 
mutations are found in less than 10% of newly diagnosed CLL patients. These 
patients are usually refractory to traditional chemotherapy and, before the era of new 
therapeutic regimens, their prognosis was very poor. The proportion of TP53 
disruptions increase as CLL progresses (Rossi & Gaidano 2016; Dohner et al. 2000). 
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Novel relevant molecular mutations identified with next-generation sequencing 
techniques are NOTCH1, SF3B1, MYD88, and BIRC3. NOTCH1 gene mutations 
have been found in almost 10% of CLL patients at diagnosis. NOTCH1 mutated 
patients usually belong to the IGHV-UM group. NOTCH1 mutations are now 
known to be independent poor prognostic markers in CLL (Rossi et al. 2012). 
Almost 40% of patients also exhibit trisomy 12 in addition to NOTCH1 mutations. 
Thus, some trisomy 12 patients have poorer survival than previously assumed (Del 
Giudice et al. 2012). SF3B1 gene mutations affecting the spliceosome complex are 
found in almost 10% of CLL cases (Quesada et al. 2011). Mutations in the MYD88 
gene occur in less than 5% of patients and been found specifically in the IGHV-M 
group. Survival in this group has been high, but the final impact on the prognosis is 
not clear (Martínez-Trillos et al. 2014). Mutations in the BIRC3 gene leading to NF-
κβ activation are found in less than in 10% of CLL patients at diagnosis. BIRC3 
mutated patients have very poor prognosis. According to a new risk stratification, 
patients with BIRC3 mutation or TP53 disruptions are categorized as high-risk 
patients.  NOTCH1 and SF3B1 mutated patients are considered as intermediate-risk 
CLL patients. Patients with 11q deletions are also assigned to this risk group. Patients 
with trisomy 12 or normal karyotype are considered as low-risk CLL patients and 
only patients who have del13q14 belong to the very-low risk group (Fabbri & Dalla-
Favera 2016; Rossi & Gaidano 2016). So far, in routine clinical practice genetic risk 
stratification is performed based on FISH and TP53 mutation analysis and the new 
risk stratification is used in clinical trials. 
2.2.3 Immunodeficiency 
Patients with CLL have significant disturbances of the immune system from the early 
stages of the disease (Hamblin & Hamblin 2008). Their innate (humoral) and 
adaptive (cell-mediated) immune responses have both quantitative and qualitative 
defects (Aittoniemi et al. 1999; Ravandi & O’Brien 2006). Increased CD4+ and CD8+ 
counts can be found at an early stage of the disease (Dearden 2008). Chronic viral 
infections including cytomegalovirus may cause profound changes in T cell counts 
(Mackus et al. 2003; Pourgheysari et al. 2007). T cells also exhibit functional 
disturbances.  Particularly, T-helper activity is impaired while T-suppressor activity 
is increased (Dearden 2008). Furthermore, in the advanced stages of the CLL, the 
proportion of FoxP3+ regulatory T cells (Tregs) is increased (Beyer et al. 2005). 
Defects in T cell function lead to impaired interaction with B cells (Dearden 2008). 
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Abnormalities in T cells increase with CLL progression (Forconi & Moss 2015). 
Defects in neutrophil and monocyte functions and reduced levels and activity of 
complement proteins have also been described (Itälä et al. 1996; Schlesinger et al. 
1996). 
A significant feature of immune suppression in CLL is hypogammaglobulinemia. 
At least one serum immunoglobulin can be diminished at an early stage of the disease 
(Davey et al. 1987; Hamblin & Hamblin 2008). As the disease progresses, 
hypogammaglobulinemia becomes more severe and involves all Ig classes (Dearden 
2008; Morrison 2010). Mechanisms leading to Ig depletion in CLL are not fully 
understood. CLL cells resemble recently discovered natural Breg cells and act like 
anergic B cells reducing production of immunoglobulins by direct cell contact. 
Furthermore, the level of soluble factors essential for plasma cell survival decreases 
and production of immunosuppressive IL-10 is increased (Forconi & Moss 2015). 
A correlation between the degree of hypogammaglobulinemia and bacterial 
infections and survival has been shown (Dearden 2008; Morrison 2010). In some 
studies, no differences were detected between Ig levels with regard to the IGHV 
mutation status (Francis et al. 2006; Sinisalo et al. 2004). 
2.2.4 Treatment 
Treatment of CLL should be initiated only when there is evidence of progressive or 
symptomatic disease (Hallek et al. 2018). The Binet classification, where CLL is 
divided into groups A (early stage of the disease), B (intermediate), or C (advanced 
stage), depending on the distribution of lymphadenopathy and presence of anemia 
and/or thrombocytopenia, is still in use in the staging of the disease (Binet et al. 
1981). Based on the genetic risk stratification chemoimmunotherapy (CIT), in which 
chemotherapy agents are combined with CD20 monoclonal antibody (mAb), is still 
the standard therapy for previously untreated IGHV-M CLL patients without TP53 
aberrations (Parikh 2018). A combination of chemotherapy agents fludarabine and 
cyclophosphamide and anti-CD20 mAb rituximab (FCR) is used for young patients 
in good physical condition (Hallek et al. 2010). Another commonly used CIT 
regimen is a combination of bendamustine and rituximab (BR) particularly for 
patients over 65 years of age (Fischer et al. 2012). For older adults with significant 
comorbidities, the current standard treatment regimen is a combination of 
chemotherapy agent chlorambucil and anti-CD20 mAb obinutuzumab (Goede et al. 
2015). For previously untreated CLL patients with the 17p13 deletion or TP53 
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mutation, ibrutinib, a Bruton´s tyrosine kinase (BTK) inhibitor, is the current 
standard treatment (Ahn et al. 2018; O’Brien et al. 2018). 
For relapsed or CIT refractory patients, novel targeted agents are the most 
preferable option. The alternative regimens are ibrutinib, BCL2 inhibitor venetoclax, 
particularly in combination with anti-CD20 mAb, or PI3Kδ inhibitor idelalisib in 
combination with rituximab (Furman et al. 2014; Kater et al. 2019; O’Brien et al. 
2018). For younger patients in good physical condition who carry TP53 
abnormalities, allogeneic HSCT is also an option to consider (Dreger et al. 2018). 
The rate of infections has not been significantly lower with novel regimens 
compared to CIT (Woyach et al. 2018). In the randomized studies, upper respiratory 
infections and pneumonia have been common infectious complications 
(Maschmeyer et al. 2019; Woyach et al. 2018).   
 
2.3 Indoleamine 2,3-dioxygenase (IDO) 
2.3.1 Background 
The essential amino acid L-tryptophan (trp) is a precursor of serotonin, melatonin, 
and vitamin B3 (niacin). Trp is also required for protein synthesis (Le Floc’h et al. 
2011; Stavrum et al. 2013). It is metabolized into kynurenine (kyn) through the kyn 
pathway leading to trp degradation (Figure 1). In this pathway, the initial rate-limiting 
step is catalyzed by IDO (Mellor & Munn 1999). IDO2 is structurally similar to IDO 
and catabolizes also tryptophan. IDO and IDO2 are encoded by genes IDO1 and 
IDO2, respectively (Ball et al. 2007; Ball et al. 2009; Munn & Mellor 2016). IDO1 is 
located adjacent to IDO2 in the short arm of chromosome 8 (Ball HJ 2009; Najfeld 
et al. 1993). IDO1 expression is regulated by interferons (IFNs) and enhanced by 
other inflammatory agents, such as bacterial lipopolysaccharide, interleukins (ILs), 
and tumor necrosis factor alpha (TNF-α) (Hissong et al. 1995; Robinson et al. 2003). 
IFNs induce immune regulatory responses mediated by IDO (Mellor & Munn 1999). 
IDO is expressed at least in macrophages, epithelial cells, DCs, and fibroblasts. In 
contrast, lymphoid cells rarely express IDO (Kahler & Mellor 2009). IDO2 
expression is found particularly in the kidney (Ball et al. 2007). The biological role of 
IDO2 is not clear, but it may also be active in immunomodulation (Ball et al. 2009). 
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IDO suppresses T cell responses via the kyn and downstream metabolites (Mellor 
& Munn 1999). Trp depletion also arrests lymphocyte cell cycle progression and 
causes naive T cells to differentiate into regulatory T-cells (Treg) (Fallarino et al. 
2006; Munn et al. 1999). FoxP3+ Treg cells are activated, increasing tolerance to 
inflammatory signals. IDO activity and expression are elevated in many chronic 
inflammatory diseases, infections, autoimmune diseases, and tumors (Mellor et al. 
2017). Overexpression of IDO in tumors occurs in tumor cells or associated cells 
like DCs, macrophages, or endothelial cells. Elevated IDO expression mediates 
tolerogenic responses to tumor cells. Activation of suppressive Treg cells by IDO 
expressing antigen-presenting cells upregulates programmed cell death protein 1 
(PD-1) expression and suppresses immune response against apoptotic tumor cells, 
thereby promoting tumor growth (Munn & Mellor 2016). 
Overexpression of IDO has been found in many tumors including colon cancer, 
lung cancer, melanoma, and breast cancer (Brandacher et al. 2006; Curti et al. 2009; 
Isla Larrain et al. 2014; Schafer et al. 2016). In cancer immunotherapy, IDO may 
present a feasible target. IDO inhibitor drugs could enhance the immune responses 
triggered by other agents. Clinical trials in which IDO inhibitors are combined with 
chemotherapy, checkpoint inhibitors, or vaccines are ongoing (Munn & Mellor 
2016). 
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Figure 1.  The kynurenine pathway of tryptophan metabolism (modified from Curti et al. 2009). 
2.3.2 IDO in hematological malignancies 
A few studies are available concerning IDO activity and expression in hematological 
malignancies. In a study with acute myeloid leukemia (AML) patients, the kyn/trp 
ratio was elevated, suggesting a raised IDO activity in AML compared to healthy 
controls (Corm et al. 2009). In another study, a significant portion of AML cells 
expressed IDO, whereas IDO was not detected in normal hematopoietic bone 
marrow cells. IDO expressed in AML cells was also found to be active, leading to 
depletion of trp (Curti et al. 2007). Furthermore, the proportion of FoxP3+ Treg cells 
was significantly increased in IDO expressing AML cells at diagnosis by tryptophan 
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catabolism compared to healthy controls or AML cells that did not express IDO. In 
a mouse model, the formation of Tregs was blocked by IDO inhibitor 1-methyl 
tryptophan (Curti et al. 2007). Nimesulide, cyclooxygenase (COX)-2 inhibitor, has 
also been shown to inhibit IDO by depleting trp and abrogating kyn release in AML 
cells. IDO1 gene expression was also reduced in these cells. Furthermore, number 
of FoxP3+ Treg cells was diminished after exposure to nimesulide (Iachininoto et al. 
2013). High IDO1 expression has also been found to impact prognosis of AML. In 
a study with 286 AML patients, high IDO1 expression correlated with a lower 
complete remission rate, and shorter overall and relapse-free survival (Chamuleau et 
al. 2008). 
Increased IDO activity has been detected also in patients with multiple myeloma. 
In a study with 25 myeloma patients, 75% of patients showed increased kyn 
concentrations. Kyn was significantly increased particularly in patients with a more 
advanced stage of the disease. IDO activity also correlated with the expansion of 
functional Treg cells (Bonanno et al. 2012). In a recent study, IL-32 secreted by 
myeloma cells promoted IDO production in macrophages (Yan H et al. 2019). 
In Hodgkin’s lymphoma, high IDO expression has been shown in macrophages, 
DCs, and endothelial cells primarily in the mixed cellular type of the disease, but not 
in Hodgkin Reed Stenberg cells or lymphocytes. High IDO expression has also been 
found to correlate with significantly shortened survival (Choe et al. 2014). 
 
2.4 Pneumococcal vaccines 
2.4.1 Polysaccharide vaccine 
The whole cell vaccine was the first pneumococcal vaccine studied in a clinical trial 
conducted in South African gold miners in 1911 (Austrian 1977). After the serotype 
specificity of pneumococcal infection was discovered, the serotype-specific 
pneumococcal polysaccharide vaccines (PPVs) replaced the whole cell vaccine 
(Geno et al. 2015). 14-valent PPV was introduced in 1977 and it was expanded to 
23-valent (PPV23) in 1983 (Grabenstein & Klugman 2012). PPV23 is the only 
currently available polysaccharide (PS) vaccine.  
PPV23 contains polysaccharides of 23 different serotypes. As polysaccharide 
antigens are T-independent, they exhibit poor immunogenic efficacy in young 
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children (Timens et al. 1989). PPV23 causes depletion of the peripheral memory B-
cell population. Hence, antibody concentrations after subsequent doses of PPV23 
are similar to or even lower than those seen after the primary dose. This 
phenomenon is called hyporesponsiveness (Clutterbuck et al. 2012). PPV23 has 
limited efficacy against IPD also in adults (Andrews et al. 2012; Huss et al. 2009). 
2.4.2 Conjugate vaccine 
Pneumococcal conjugate vaccines (PCVs) are immunogenic also in young infants 
and children (Black et al. 2000). Conjugation of a pneumococcal polysaccharide to a 
carrier protein enhances the immunogenicity of the polysaccharide. Conjugation 
transforms the T-cell independent polysaccharide vaccine to a T-dependent 
conjugate vaccine. PCVs’ capability of creating immunological memory induces 
responsiveness to subsequent doses of vaccine. Antibodies generated by PCVs have 
higher avidity with better functional capacity (Geno et al. 2015; Pichichero 2013). 
Furthermore, PCVs reduce nasopharyngeal carriage, which is considered critical for 
the formation of herd immunity (Rashid et al. 2012). The serotypes included in PCVs 
have been selected on the basis of serotypes causing IPD in children (Rodgers & 
Klugman 2011). PCV7 was licensed in the US in 2000. Since then, PCV10 and 
PCV13 have been developed. PCV7 contained capsular PSs of serotypes 4, 6B, 9V, 
14, 18C, 19F, and 23F. Serotypes 1, 5, and 7F were added to PCV10 and the currently 
used PCV13 also includes serotypes 3, 6A, and 19A (Geno et al. 2015). 
Four carrier proteins have been used in pneumococcal conjugate vaccines. In 
PCV10 each serotype is conjugated to tetanus toxoid, diphteria toxoid, or a 
recombinant Haemophilus influenzae protein D. All serotypes of PCV7 and PCV13 are 
conjugated to genetically modified cross-reacting material of diphteria toxin 
(CRM197) (Geno et al. 2015; Pichichero 2013). 
2.4.3 Vaccination studies in hematological malignancies 
The majority of pneumococcal vaccination studies in hematological malignancies 
have been performed in HSCT recipients. A randomized study of EBMT compared 
early administration of PCV with late vaccination after allogeneic HSCT. In the early 
vaccination group, a course of three doses of PCV7 given 1 month apart was initiated 
3 months and in the late group 9 months after transplantation. The antibody 
response rate seen in the early vaccination group one month after the last PCV7 dose 
31 
was similar to the rate in the late group, indicating the benefits brought by earlier 
protection against IPD in these high-risk patients. However, at 1 year after HSCT, 
antibody concentrations in the early group declined significantly compared to the 
late group. Furthermore, after a single dose of PPV23 given at 12 and 18 months in 
the early and in the late group, respectively, 41% of the patients who were non-
responders to PCV7 achieved a response (Cordonnier et al. 2009). PPV23 also 
expanded the serotype coverage for the antigens 1 and 5, which are not included in 
PCV7 (Cordonnier et al. 2010). Antibody persistence among long-term survivors in 
the same study population was also assessed 10 years after the vaccination program. 
In 40% of the patients, antibody concentrations remained at a protective level against 
IPD (Cordonnier et al. 2015). In a study with PCV13, pediatric and adult allogeneic 
HSCT recipients received three doses of PCV13 3-6 months after transplantation. A 
fourth dose of PCV13 was administered 6 months later and a dose of PPV23 1 
month from the last dose of PCV13. After the third dose, antibody concentrations 
increased significantly for all PCV13 serotypes from the baseline. Before the fourth 
dose of PCV13, antibody concentrations declined but significantly increased again 
after the fourth dose. After the dose of PPV23, there were no changes in antibody 
concentrations (Cordonnier et al. 2015). 
Since the beginning of the 21st century, only a few studies have been carried out 
on pneumococcal vaccines in patients with CLL. Most studies with PPV23 have 
shown no significant antibody responses (Hartkamp et al. 2001; Sinisalo et al. 2001). 
In addition, the administration of 3 doses of granulocyte-macrophage-colony-
stimulating factor (GM-CSF) before or after the PPV23 did not improve antibody 
response (Safdar et al. 2008). Furthermore, ranitidine treatment inhibiting the 
histamine effect, thereby probably enhancing immunoglobulin production, did not 
improve antibody response to PPV23 (van der Velden et al. 2007). PCVs, in contrast, 
have shown efficacy in inducing antibody response in CLL patients. In a study with 
PCV7, almost 40% of CLL patients achieved a significant antibody response to at 
least six PCV7 antigens when the vaccine was administered at an early stage of the 
disease. Compared to immunocompetent controls, antibody concentrations were 
significantly lower in CLL patients after vaccination (Sinisalo et al. 2007). To date, 
two studies have been carried out on PCV13. In a study of 24 untreated CLL patients 
and 15 controls without previous PPV23 vaccination, 58% of the patients and all 
controls achieved at least a two-fold increase in antibody titers from the baseline 
with one dose of PCV13. The proportion of plasmablasts, suggesting early response 
to vaccination and stimulation of the immune system, was significantly higher than 
the baseline in CLL patients after vaccination while remaining significantly lower 
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than in controls (Pasiarski et al. 2014). In a recent randomized study, PCV13 was 
compared to PPV23 in untreated CLL patients. Functional antibody titers measured 
by opsonophagocytic assay (OPA) were significantly higher for 11 out of the 13 
serotypes with PCV13 at one month after vaccination and for 6 out of the 13 
serotypes at six months after vaccination compared to PPV23. All antibody 
responses for PPV23 were inferior to those generated by PCV13 (Svensson et al. 
2018). Serotype-specific antibody responses are available from two studies (Table 1). 
In patients with multiple myeloma, the immunogenicity of PPV23 is also poor. 
Only 33% of patients achieved a response to PPV23 when administrated before 
autologous HSCT at the time of peripheral stem cell harvest (Hinge et al. 2012). 
Instead, in a study with 20 patients with smoldering multiple myeloma, 60% of the 
patients achieved a significant antibody response for PCV7 serotypes measured by 
enzyme-linked immunosorbent assay (ELISA) after one dose of PCV13 at one 
month after vaccination. A significant response was achieved in 40% of the patients 
measured by OPA, defined as at least a 4-fold increase from the baseline. At 6 
months after vaccination, 35% of the patients fulfilled the same response criteria by 
ELISA and 30% by OPA. At 12 months, these percentages were only 25 (ELISA) 
and 10% (OPA) (Bahuaud et al. 2017). 
2.4.4 Vaccination guidelines 
In the guidelines in place in the United States, PPV23 is recommended no less than 
8 weeks after PCV13 to adults 19 years of age and older with immunocompromising 
conditions. A second dose of PPV23 is recommended 5 years after the first dose 
(Bennett et al. 2012). Furthermore, PPV23 is recommended for all adults 65 years of 
age and older one year after a dose of PCV13, or later (Kobayashi et al. 2015). In the 
guidelines of the European Conference on Infectious in Leukaemia (ECIL) group 
for patients with hematological malignancy, PCV13 followed by PPV23 no less than 
8 weeks later is recommended to patients with multiple myeloma, lymphoma, and 
CLL before treatment. Patients with AML and myelodysplastic syndromes (MDS) 
are recommended to vaccinate 3-6 months after chemotherapy (Mikulska et al. 
2019). 
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Table 1.  Response rates in studies with pneumococcal conjugate vaccine in patients with CLL. 
 
Serotype 
 Sinisalo et al. 2007 Svensson et al. 2018 
Vaccine PCV7 PCV13 
Method ELISA OPA 
 Response rate (%)a %b 
4 
6B 
9V 
14 
18C 
19F 
23F 
35 
43 
20 
39 
43 
47 
47 
61 
59 
52 
78 
79 
49 
48 
aDefined as an at least 2-fold increase and a post-vaccination concentration of at least 0.35 µg/ml 
bOPA-titer ≥ LLOQ (lower limit of quantification) 
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3 AIMS OF THE STUDY 
The main objectives of this study were to gain better understanding of the 
characteristics of IPD in patients with hematological malignancies, assess efficacy of 
pneumococcal vaccines especially in patients with CLL, and discover possible factors 
contributing to the vaccine responses in CLL patients. 
The specific aims were: 
 
1.  To evaluate IDO activity and IDO1 and IDO2 gene expression in CLL. 
 
2. To determine the incidence of IPD, serotype distribution, and serotype 
 coverage of pneumococcal conjugate and polysaccharide vaccines in patients 
 with specific hematological malignancies. 
 
3. To assess antibody persistence in patients with CLL five years after the 
 administration of PCV7. 
 
4. To evaluate the efficacy of the PPV23 booster dose given five years after 
 PCV7 in patients with CLL. 
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4 MATERIALS AND METHODS 
4.1 Subjects and controls 
4.1.1 Study I 
For measurements of IDO activity, the study population included 49 patients with 
CLL and 24 age- and sex-matched controls from Tampere and Turku University 
Hospitals who had participated in an earlier vaccine response study with PCV7. A 
majority of the patients had an early stage disease. According to the Binet 
classification, 39 patients had stage A disease and 9 patients had stage B disease while 
1 patient had stage C disease. Eleven patients had received chemotherapy (Sinisalo 
et al. 2007). The study population for IDO1 and IDO2 gene expression comprised 
10 CLL patients and 7 controls. All 10 untreated CLL patients had stage A disease 
according to the Binet classification. 
4.1.2 Study II 
In Finland, clinical microbiology laboratories are required to report bacterial 
isolations from blood and cerebrospinal fluid (CSF), including S.pneumoniae, to the 
National Infectious Disease Register (NIDR), a population-based laboratory 
surveillance system. A case of IPD was defined as isolation of S.pneumoniae from 
blood and/or CSF during 1995-2002. To find data concerning diagnosis of specific 
hematological malignancy (Hodgkin´s lymphoma, non-Hodgkin´s lymphoma, 
myeloma, or leukemia), national IPD surveillance data were linked to the Finnish 
Cancer Registry database (Brenner & Hakulinen 2005; Klemets et al. 2008). 
Additionally, ICD (9th and 10th Revision) codes of hematological malignancy for the 
IPD episode were collected from the National Hospital Discharge Register 
(HILMO). The diagnoses of hematological malignancy within one year prior to the 
first episode of IPD were only analyzed to maintain the cumulative incidence of 
hematological malignancies constant. Of the total of 4611 IPD cases identified, only 
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the first episodes of disease (n=4357) were included in the analysis (Klemets et al. 
2008). A hematological malignancy (Hodgkin’s or non-Hodgkin’s lymphoma, 
myeloma, or leukemia) had been diagnosed in 56 (1.3%) cases within one year prior 
to the IPD episode. Of these 56 S.pneumoniae isolates from patients with 
hematological malignancy and IPD, the strain was available for serotyping in 47 cases 
(84%). The median age of these patients was 64 years (range 9 months-81 years) at 
the time of IPD and 68% (n=32) of the isolates were from males. The isolation of 
bacteria was performed in 45 cases from blood (96%) and from CSF in 2 cases 
(4.3%). Only three patients had a specific CLL diagnosis. 
4.1.3 Studies III and IV 
The study population comprised 24 CLL patients (12 males and 12 females), with a 
median age of 64 years (range 47-86 years) from Tampere and Turku University 
Hospitals (Table 2). The control population consisted of eight subjects (median age 
67 years, range 57-82 years, four males and four females) without any known 
immunological defects or hematological diseases from Tampere University Hospital. 
The patients and controls had participated in an earlier pneumococcal conjugate 
vaccine response study with PCV7 (Sinisalo et al. 2007). In study III, the disease 
status according to the Binet classification was A in 16, B in 2, and C in 6 patients. 
A total of 16 patients had never been treated for CLL. Seven patients had suffered 
from severe infections (requiring intravenous antibiotics or hospitalization) and six 
patients from mild to moderate infections (treated with oral antibiotics) during the 
five years since PCV7 vaccination. Only one of these infections was pneumococcal 
infection, i.e. pneumococcal septicemia.  Hypogammaglobulinemia (S-IgG <6.77 
g/l) was detected in 11 patients. 
In study IV, samples taken after PPV23 administration were not available in the 
case of four patients. Hence, the final study population in study IV comprised 20 
CLL patients and 8 controls. According to the Binet classification, the disease status 
for these patients was A in 12, B in 2, and C in 6 patients. Thirteen patients had 
never been treated for CLL. Six patients had received CIT or chemotherapy, one 
patient CD52 monoclonal antibody (alemtuzumab) after chemotherapy, and one 
patient had received allogeneic HSCT. Hypogammaglobulinemia as defined above 
was detected in nine (45%) patients. Of these 20 patients, five had suffered from 
severe infections and five from mild to moderate infections during the 5 years since 
PCV7 vaccination. Only one of these infections was invasive pneumococcal disease. 
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Table 2.  Clinical and laboratory characteristics of patients with CLL in studies III and IV. 
Character Patients with CLL (n=24) 
Sex M/F 12/12 
Age (years) 64 (47-86) 
Binet A/B/C 16/2/6 
Past CLL therapy 8 (33%) 
Lymphocyte count, x109/l (1.2-3.5) 24.3 (0.9-140.0) 
Platelet count, x109/l (150-360) 141 (38-372) 
Hemoglobin, g/l (117-167) 135 (81-153) 
Neutrophil count, x109/l (1.6-6.2) 4.0 (0.6-12.1) 
IgG, g/l (6.77-15) 
IgM, g/l (0.36-2.84) 
IgA, g/l (0.52-4.84) 
7.4 (3.2-12.5) 
0.3 (0.1-5.4) 
0.7 (0.2-4.5) 
The values are expressed as medians and ranges 
4.2 Vaccination 
The vaccine used in study IV was 23-valent pneumococcal polysaccharide vaccine 
(Pneumovax®), which contains capsular polysaccharides of pneumococcal serotypes 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 
23F, and 33F. A dose of 0.5 ml contains 25 µg of each PS type and phenol as adjuvant 
(Robbins et al. 1983). It also contains significant amount of cell wall polysaccharide 
(Sorensen & Henrichsen 1984). Patients and controls received one intramuscular 
deltoid injection of Pneumovax® five years after PCV7. 
4.3 Samples and processing  
In study I, venous blood samples had been taken before PCV7 administration and 
stored at -20°C (Sinisalo et al. 2007). 
In studies III and IV, venous blood samples for antibody analyses were taken 
before PPV23 administration (five years after the administration of PCV7) and one 
month after PPV23. Serum was separated by centrifugation and stored at -20°C. In 
addition, venous blood samples were drawn from the CLL patients at the time of 
PPV23 administration for the analysis of total blood count and immunoglobulins. 
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4.4 Methods 
4.4.1 Determination of IDO activity and expression 
Trp (mmol/l) and kyn (µmol/l) concentrations in peripheral blood were measured 
at the Department of Microbiology and Immunology of Tampere University by 
reverse-phase high-performance liquid chromatography (HPLC). Trp was separated 
with a Shimadzu liquid chromatograph LC-10AD VP (Shimadzu Co, Kyoto, Japan) 
using a 50-mm BDS Hypersil C18 5 µm column (Thermo Electron Co, Bellefonte, 
PA, USA). Monitoring was performed by fluorescence with a Shimadzu RF-10A XL 
detector at 266 nm excitation and 366 nm emission wavelengths. Kyn was separated 
with a Hewlett Packard 1100 liquid chromatograph (Palo Alto, CA, USA) using a 
Merck LiChroCart 55-4150 mm cartridge containing a Purospher STAR RP-18 3 µm 
column (Merck Co, Darmstadt, Germany) and analyzed by ultraviolet absorption at 
360 nm wavelength with a Hewlett Packard G13144 detector. For IDO1 and IDO2 
gene analysis, blood samples were directly subjected to leukocyte separation with 
Histopaque 1077 density gradient (Histopaque-1077, cat. no. 10771, Sigma-Aldrich, 
MO, USA). The peripheral blood mononuclear cell (PBMC) layer was collected, and 
the cells were suspended into 1 ml of RPMI-1640 medium (cat. no. R0883, Sigma-
Aldrich, MO, USA). Immediately after the PBMC separation, traces of erythrocytes 
were lysed with 10 s of H2O treatment and immediately recovered with 0.9% NaCl. 
Total ribonucleic acid (RNA) extraction was performed with the Qiagen RNEasy 
Midi kit (cat. no. 75144, Qiagen, CA, USA) according to the manufacturer´s 
instructions. The RNA (500ng) was converted into complementary deoxyribonucleic 
acid (cDNA) using the High Capacity cDNA Reverse Transcription Kit (cat. no. 
4368814, Applied Biosystems, CA, USA) according to the manufacturer´s 
instructions. The isolated RNA was quantified spectrophotometrically (Nanodrop, 
Thermo Scientific, DE, USA) and tested for inhibition to achieve the correct RNA 
load for cDNA conversion. IDO activity was determined by calculating the kyn/trp 
(µmol/mmol) ratio by relating concentrations of kyn to trp. 
Levels of IDO 1 and IDO2 gene transcripts were determined via the TaqMan 
real-time polymerase chain reaction (PCR). The levels of gene transcripts were 
analyzed with a separate single IDO1 gene expression assay (cat. no. 
Hs00158027_m1, Applied Biosystems, CA, USA) and an IDO2 gene expression 
assay (cat. no. Hs00401201_m1, Applied Biosystems, CA, USA) and TaqMan real-
time PCR. 
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4.4.2 Calculation of incidence rates of IPD and serotyping 
Incidence rates of IPD among patients with hematological malignancies including 
95% confidence intervals were calculated using person-time of patients with a 
specific hematological malignancy in the Cancer Registry as a denominator. Data 
were analyzed by using SPSS Statistics 21.0 (Chicago, IL, USA). 
S.pneumoniae isolates were serotyped at the National Institute for Health and 
Welfare (THL) reference laboratory (Klemets et al. 2008). Pneumococcal serotypes 
were grouped as PCV7, PCV10, PCV13, PPV23, and all other types. 
4.4.3 Determination of pneumococcal antibodies 
The concentrations of serum IgG antibody against pneumococcal capsular PSs were 
measured at the THL laboratory by a modification of the 22F inhibition enzyme 
immunoassay (EIA) method (Simell et al. 2008). In study III, antibodies to PCV7 
serotypes 1, 3, 6B, 14, 19F, and 23F were determined. In addition, in study IV, 
together with PCV7 serotypes, PPV23 antigens 5 and 7F were determined, as an 
example of antigens which are not included in PCV7. The results are given as µg/ml 
calculated on the basis of the designated IgG values of the 89-SF reference serum 
(Simell et al. 2008). The determination limits of antibodies were 0.03 for serotype 4, 
0.04 for 6B, 9V, 18C, and 23F, 0.06 for 19F, 0.1 for 7F and 14, and 0.15 µg/ml for 
serotype 5. In study III, an antibody concentration of 0.35 µg/ml was considered as 
the threshold for protection against IPD, as recommended by the World Health 
Organization WHO (Jodar et al. 2003). In study IV, a significant antibody response 
was defined as an at least two-fold increase from the baseline and a post-vaccination 
level of at least 0.35 µg/ml consistent with an earlier PCV7 study (Sinisalo et al. 
2007). 
4.4.4 Statistical analyses 
In study I, Mann-Whitney U-test was applied in comparisons of kyn and trp 
concentrations and the kyn/trp ratio. Correlations were calculated by Spearman’s 
rank correlation test. The gene expression results were analyzed with Relative 
Quantification (RQ) documents and the RQ Manager Software for automated data 
analysis (Applied Biosystems, CA, USA). The endogenous control for transcript was 
beta-actin (BACT, cat. no. Hs03023880_g1). The calculations were based on Δ 
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threshold cycles (Ct) values obtained by deducting the Ct value of the endogenous 
control from that of the given target gene. Then, the ΔΔCt values were calculated by 
deducting the ΔCt of the calibrator from the Ct value of both target genes. The RQ 
value, which indicates the fold change for both targets, was derived from the 
formula: RQ = 2-ΔΔCt. A gene that was regulated more than twofold (≥2.0 or ≤0.5) 
was considered to be significantly regulated (Jylhävä et al. 2010). 
In study III, a comparison of antibody concentrations five years after PCV7 
administration between CLL patients and controls was performed with Fisher’s 
exact test. In study IV, antibody concentrations and proportionate changes between 
groups were compared by independent-samples Mann-Whitney test and the 
significance of antibody responses within groups by 2-tailed Fisher’s exact test. 
4.4.5 Ethical considerations 
In studies I, III, and IV, written informed consent was obtained from all patients 
and controls. Studies were approved by the ethical board of the Pirkanmaa Hospital 
District. In study II, the national registry data use was authorized by the Ministry of 
Social Affairs and Health, the Finnish Data Protection Authority, and the National 
Research and Development Center for Welfare and Health. Studies were conducted 
in accordance with the Declaration of Helsinki. 
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5 RESULTS 
5.1 IDO activity and expression in patients with CLL 
In CLL patients, the kyn/trp ratio was significantly higher than in controls, indicating 
increased IDO activity, but no statistically significant difference in kyn or trp 
concentrations was discovered. The correlation of the kyn/trp ratio was estimated 
against demographic and disease-associated parameters in CLL patients, including 
age, sex, Binet class, disease duration, immunoglobulin levels, hemoglobin level, 
blood cell counts (lymphocytes, neutrophils, thrombocytes), and C-reactive protein 
levels. A statistically significant association of kyn/trp ratio was detected with age 
(r=0.367, p=0.010) and disease duration (r=0.290, p=0.044). However, increased 
IDO activity did not affect the antibody response to PCV7 (Sinisalo et al. 2007). 
There was no difference in the kyn/trp ratio between responders and non-
responders among CLL patients, and no significant correlations between the kyn/trp 
ratio and serotype-specific responses were found. 
Instead of increased IDO activity in CLL patients, a significantly reduced 
expression of IDO1 and IDO2 genes was detected in PBMCs. Kyn and trp 
concentrations, the kyn/trp ratio, and IDO1 and IDO2 gene RNA expression in 
PBMCs in patients with CLL and controls are shown in Table 3. 
Table 3.  Kynurenine and tryptophan concentrations and their ratio (kyn/trp) and IDO1 and IDO2 
gene RNA expression in peripheral blood mononuclear cells in patients with CLL and controls. 
Character CLL 
n=49 
Controls 
n=24 
 
p-value  
Kyn/trp ratio, Imol/mmol 37 (31-48) 33 (29-38)  0.027 
Kynurenine, Imol/l 3.6 (2.7-4.6) 3.1 (2.6-3.8) 0.260 
Tryptophan, mmol/l 0.094 (0.083-0.107) 0.095 (0.083-0.112) 0.425 
 n=10 n=7 RQ 
IDO1, Av ΔCt 14.18 11.63 0.17 
IDO2, Av ΔCt 15.36 12.26 0.12 
Abbreviations: Av ΔCt, average (mean) Δ threshold cycles; RQ relative quantification 
The results are expressed in medians (quartiles) unless otherwise stated 
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5.2 IPD in Finnish patients with hematological malignancies 
The overall incidence rate of IPD among patients with hematological malignancies 
was 3.8 per 1000 person-years (Table 4). Patients with multiple myeloma had the 
highest rate of IPD (10.9 cases per 1000 person-years). The most common 
pneumococcal serotypes were 14 (n=8, 17%), 6B (n=5, 11%), 11 (n=3, 6.5%), 4 
(n=3, 6.5%), and 19F (n=2, 4.3%). Of the serotyped isolates, 24 (51%), 27 (57%), 
and 30 (64%) were serotypes covered by PCV10, PCV13 and PPV23, respectively 
(Figure 2). A total of 15 out of the 47 (32%) isolates were not included in either 
PPV23 or PCV13.  Serotype coverage varied in line with the type of hematological 
malignancy: In patients with myeloma, the serotypes included in PCV13 and PPV23 
covered 12 (60%) and 14 (70%) of cases, respectively (Figure 3). 
Table 4.  Rates of invasive pneumococcal disease (IPD) in patients with hematological 
malignancy in Finland 1995-2002 within one year of hematological diagnosis. 
Malignancy Cases of 
specified malignancy  
(person-years)a 
IPD cases with 
specified malignancy 
Incidence rate/1000 
person years  
(95% CI) 
Myeloma 2393 26 11 (7.4-16) 
Any leukemia 4201 17 4.1 (2.5-6.5) 
NHL 7131 12 1.7 (1.0-3.0) 
HL 1080 1 0.9 (0.1-6.6) 
Total 14805 56 3.8 (2.9-4.9) 
Abbreviations: HL Hodgkin’s lymphoma; NHL  Non-Hodgkin’s lymphoma 
aFrom Finnish Cancer Registry 
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Figure 2.  Distribution of serotypes causing IPD in patients with hematological malignancies in Finland during 1995-2002 within one year of diagnosis and 
serotype coverages of pneumococcal conjugate vaccines. 
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Figure 3.  Number of IPD causing serotypes covered by pneumococcal vaccines in patients with 
hematological malignancies in Finland 1995-2002 within one year of diagnosis. 
5.3 Antibody persistence after pneumococcal conjugate vaccine 
In CLL patients, median antibody concentrations against pneumococcal serotypes 
4, 6B, 18C, and 19F five years after PCV7 administration were approximately 50% 
lower than those measured four weeks after vaccination. Antibody concentrations 
against serotypes 9V and 23F were approximately 75% and 65% lower five years 
after vaccination, respectively. In contrast, the median concentration of the antibody 
against serotype 14 persisted at a similar level over the five-year period following the 
vaccination. In controls, antibody concentrations declined by more than 50% in each 
serotype group. The biggest decrease in controls was against serotype 9V, i.e. 95%. 
Between CLL patients and controls, no statistically significant differences were seen 
in antibody concentrations five years from vaccination (Table 5). 
The baseline proportions of suggested protective antibody concentrations before 
a booster vaccination in patients with CLL ranged from 8 to 88%. The lowest 
baseline proportion was against serotype 4 and the highest against serotype 19F. In 
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controls, the same percentages were 0-100%, with no protective concentrations 
found against serotype 4. Protective antibody concentrations against serotype 18C 
were observed in all controls before vaccination. After five years of PCV7, the 
antibody concentrations in 29 to 71% of CLL patients, depending on serotype, 
remained at a level suggested to be protective against IPD (Figure 4). The lowest 
proportion was found against serotype 4 while the highest was against serotypes 18C 
and 19F. In controls, the corresponding percentages ranged from 50 to 87.5%, with 
the lowest proportion being against serotype 6B and the highest against serotype 
18C. 
Table 5.  Antibody concentrations against pneumococcal antigens of 7-valent conjugate vaccine 
four weeks and five years after vaccination in patients with CLL and in controls. 
Serotype Post-PCV antibody 
level median (quartiles) 
5 yrs post-PCV antibody level median 
(quartiles) 
p-valuea 
CLL Control CLL Control 
4 0.30 (0.07-1.22) 1.87 (0.43-6.16) 0.15 (0.02-0.40) 0.52 (0.13-0.90) 0.116 
6B 0.55 (0.20-1.82) 0.95 (0.23-14.7) 0.29 (0.09-0.94) 0.39 (0.06-1.24) 1.000 
9V 1.40 (0.25-7.12 18.0 (0.34-63.2) 0.33 (0.15-2.33) 0.97 (0.17-5.06) 0.685 
14 0.72 (0.31-2.66) 14.7 (1.01-20.5) 0.73 (0.20-4.01) 2.71 (0.45-5.83) 0.676 
18C 1.55 (0.81-5.99) 9.76 (4.65-81.1) 0.73 (0.23-3.06) 1.42 (1.00-2.47) 0.642 
19F 2.01 (0.61-9.31) 3.26 (1.20-51.1) 1.07 (0.26-2.88) 0.69 (0.31-1.56) 1.000 
23F 1.53 (0.66-13.4) 5.11 (0.98-23.0) 0.51 (0.17-1.56) 1.17 (0.11-2.23) 1.000 
aFisher´s exact test 
aBetween CLL patients and controls five years from vaccination 
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Figure 4.  The proportions of antibody concentrations suggestive of protection (≥0.35 µg/ml) against 
pneumococcal antigens of 7-valent pneumococcal conjugate vaccine in patients with CLL 
and in controls (ctrl) five years after vaccine administration. 
5.4 Antibody response of pneumococcal polysaccharide 
vaccine given five years after conjugate vaccine 
 
Only 10 to 15% of CLL patients achieved a significant response to PCV7 antigens 
defined as an at least two-fold increase and a post-vaccination concentration of at 
least 0.35 µg/ml (Table 6). The responders were the same four patients, depending 
on the serotype. In controls, 75-88% achieved a significant response to PCV7 
antigens 4, 6B, 9V, 14, 18C, and 19F. In contrast, the corresponding rate for serotype 
23F was only 50%. For PPV23 antigens 5 and 7, the corresponding percentages of 
responders in CLL patients were 20% and 15%, respectively. All controls achieved 
a significant response to PPV23 antigens. Antibody concentrations after PPV23 
were significantly higher in controls for four PCV7 antigens (4, 9V, 14, and 18C) and 
for both PPV23 antigens (Table 7). In contrast, no difference was observed in 
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antibody concentrations for PCV7 antigens 6B, 19F, and 23F. No vaccine-related 
adverse events were reported. 
Table 6.  Significant response rates and post-vaccination antibody concentrations suggestive of 
protection (≥0.35 =g/ml) to the seven serotypes included in PCV7 (bold) and to the two serotypes 
included in PPV23 in patients with CLL and controls. 
 Response ratea  Post-vaccination concentration ≥0.35 =g/ml 
 CLL  Controls  CLL  Controls 
Serotype n=20 (%)  n=8 (%) p-valueb n=20 (%)  n=8 (% 
4 2 (10) 
4 (20) 
2 (10) 
3 (15) 
3 (15) 
2 (10) 
2 (10) 
3 (15) 
2 (10) 
 7 (88) 
8 (100) 
6 (75) 
6 (75) 
7 (88) 
7 (88) 
6 (75) 
7 (88) 
4 (50) 
<0.001 7 (35) 
6 (30) 
10 (50) 
14 (70) 
13 (65) 
12 (60) 
15 (75) 
15 (75) 
13 (65) 
 8 (100) 
8 (100) 
7 (88) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
5  <0.001  
6B  0.002  
7F  <0.001  
9V  0.001  
14  <0.001  
18C  0.002  
19F  0.001  
23F  0.038  
aDefined as an at least 2-fold increase and a post-vaccination concentration of at least 0.35 =g/ml 
bBetween significant response rates in patients with CLL and controls 
bFisher´s exact test 
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Table 7.  
Pre- and post-vaccination (PPV23) antibody concentrations to seven serotypes included in the 7-valent pneumococcal conjugate vaccine 
(bold) and two serotypes included in the 23-valent pneumococcal polysaccharide vaccine in CLL patients and in controls. 
Serotype 
Pre-vaccination antibody 
concentration GMC (8g/ml) (quartiles) 
 
Post-vaccination antibody                         
concentration GMC (8g/ml) (quartiles) 
p-value a 
CLL (n=20) 
Control (n=8) 
CLL (n=20) 
Control (n=8) 
4 
0.12 (0.02-0.40) 
0.34 (0.13-0.90) 
0.13 (0.02-0.67) 
1.96 (1.36-2.82) 
<0.001 
5 
0.16 (0.08-0.44) 
0.15 (0.08-0.25) 
0.22 (0.08-0.64) 
2.20 (0.53-5.57) 
0.002 
6B 
0.46 (0.11-1.69) 
0.30 (0.06-1.24 
0.56 (0.14-3.39) 
2.28 (0.75-9.96) 
0.063 
7F 
0.38 (0.07-1.27) 
0.56 (0.31-1.23) 
0.55 (0.07-1.83) 
6.74 (2.97-13.8) 
<0.001 
9V 
0.51 (0.23-2.33) 
0.91 (0.17-5.06) 
0.62 (0.32-2.29) 
3.04 (0.58-12.1) 
0.033 
14 
0.77 (0.20-4.14) 
1.56 (0.45-5.83) 
0.96 (0.17-6.20) 
6.65 (3.00-24.0) 
0.021 
18C 
0.93 (0.26-3.06) 
1.55 (1.00-2.47) 
1.06 (0.27-4.07) 
6.81 (3.82-15.7) 
0.010 
19F 
0.97 (0.30-2.88) 
0.83 (0.31-1.56) 
1.29 (0.33-4.20) 
4.18 (1.88-6.05) 
0.055 
23F 
0.53 (0.14-1.56) 
0.82 (0.25-2.23 
0.67 (0.13-4.41) 
2.29 (2.07-3.32) 
0.150 
Abbreviation: GMC geometric mean concentration 
aBetween post-vaccination concentrations in patients with CLL and controls 
aIndependent-samples Mann-W
hitney U-test (statistical significance if P ≤ .05) 
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6 DISCUSSION 
This study focused on antibody persistence after pneumococcal conjugate vaccine 
and antibody response to the pneumococcal polysaccharide booster vaccine in CLL 
patients. Furthermore, the coverage of pneumococcal vaccines was analyzed. 
Another main goal was to estimate IDO activity and expression in CLL patients and 
to evaluate the possible impact of IDO on vaccine responses. Furthermore, this 
study assessed the incidence of IPD, serotype distribution, and coverage of 
pneumococcal vaccines in patients with hematological malignancies in Finland. 
6.1 IDO and immune dysregulation in CLL 
IDO activity was found to be increased in CLL patients based on their elevated 
kyn/trp ratio. This finding was consistent with other studies concerning IDO in 
hematological malignancies (Bonanno et al. 2012; Corm et al. 2009). IDO expression 
in PBMCs of CLL patients was reduced, suggesting that the observed IDO activity 
was derived from cells other than malignant B-lymphocytes. This finding has been 
confirmed with patients with Hodgkin’s lymphoma, who express IDO in the 
microenvironment, but not in tumor cells or lymphocytes (Choe et el. 2014). As 
stated above, IDO expression is uncommon in lymphocytes (Kahler & Mellor 2009). 
Instead, AML blast cells have been shown to express IDO by themselves 
(Chamuleau et al. 2008; Curti et al. 2007). 
Naive T-cells convert into Treg cells via IDO production and tryptophan 
catabolism (Fallarino et al. 2006). Treg cells play an important role in creating a 
tolerogenic microenvironment contributing to growth and survival of cancer cells 
(Munn & Mellor 2016; Ricciuti et al. 2018). An increased frequency of Treg cells has 
been discovered in AML, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple 
myeloma, and myelodysplastic syndrome (Beyer et al. 2006; Kordasti et al. 2007; 
Marshall et al. 2004, Wang et al. 2005; Yang et al. 2006). Increased frequencies of 
CD4+CD25+ Treg cells have also been shown in patients with CLL, particularly in 
the advanced stage of the disease (Beyer et al. 2005). Although IDO expression via 
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increased IDO activity in CLL patients seems to originate from cells other than CLL 
cells themselves, as indicated by our data, it may play a role in the creation of an 
immunosuppressive microenvironment leading to tolerance to cancer cells. 
Only very limited data is available concerning the role of Treg cells in vaccine 
responses. In a study with Gambian infants, Treg cells were found to suppress 
antibody response to measles vaccination but not to diphtheria-tetanus-pertussis 
vaccine (Ndure et al. 2017). In a study with hemodialysis patients, IDO levels were 
higher in patients with insufficient response to hepatitis B vaccine, compared to 
patients with adequate response (Eleftheriadis et al. 2011). In our data, we did not 
observe any impact of elevated IDO activity on vaccine antibody response. 
6.2 Features of IPD in hematological malignancies 
The risk of IPD in patients with hematological malignancies was 35 times higher 
than in the general population in Finland, where the average annual incidence of IPD 
was 0.11 cases per 1000 persons (Klemets et al. 2008). As established by earlier data, 
the highest rates were seen in patients with myeloma (Wong et al. 2010). The risk of 
IPD could have been expected to be even higher over a longer follow-up period. 
The pneumococcal serotype distribution among patients with hematological 
malignancy before the introduction of the infant conjugate vaccine program was 
different from serotypes causing IPD among the general population, as the most 
common serotypes among the general adult population were 4, 14, 3, 7F, and 23F 
and serotypes 6B, 14, 19A, 18C, and 7F among children (Klemets et al. 2008). 
Serotypes 14, 3, 7F, and 4 were also the most common ones among adults in 2001-
2003 in North-Rhine Westphalia, Germany (Reinert et al. 2005). All the most 
common serotypes in our data were included in PPV23, but serotype 11 was not 
included in PCV13. Among the general population above the age of 18 in Finland, 
the serotype coverage of PCV13 and PPV23 was 1.3-fold higher than in the 
hematological patients in our study (Klemets et al. 2008). Among hematological 
patients and hematopoietic stem cell transplant recipients in France, the serotype 
coverage of PCV13 and PPV23 was 84% and 92%, respectively (Debbache et al. 
2009). Hence, the proportion of those serotypes which were not covered in both 
PPV23 and PCV13 was relatively high in our study. The possible differences in 
serotype distribution and lower serotype coverage of pneumococcal vaccines may 
reduce the benefits from herd immunity. Patients with hematological malignancy 
would probably gain more protection against IPD from pneumococcal conjugate 
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vaccines with expanded serotype coverage as 15-valent pneumococcal conjugate 
vaccine (McFetridge et al. 2015). 
6.3 Antibody persistence in patients with CLL 
In patients with CLL, pneumococcal antibody concentrations declined during the 
five years following a single dose of PCV7 for six out of seven serotypes. In healthy 
controls, decline was seen for all serotypes. No statistically significant difference was 
seen between these two groups in median antibody concentrations. However, a trend 
toward lower antibody concentrations in CLL patients was seen compared to 
controls for all serotypes except for serotype 19F. The median antibody 
concentrations in CLL patients at five years after PCV7 administration, as compared 
with the baseline levels before vaccination, varied depending on the serotype. The 
post-vaccination antibody concentrations for serotypes 4 and 14 were 1.6- and 1.3 
times higher than the baseline, respectively. In contrast, for serotypes 6B and 18C, 
the median antibody concentrations declined by almost 20% during the follow-up 
period. Antibody concentrations for the other three serotypes declined to baseline 
levels. However, in more than half of the CLL patients, the antibody concentrations 
remained at a level considered to be protective against IPD for four out of seven 
serotypes five years after PCV administration. Most of the patients had never been 
treated for CLL, which may have an impact on antibody persistence. The relatively 
low rates of hypogammaglobulinemia may also contribute to better antibody 
persistence. 
There is no earlier data available concerning pneumococcal antibody persistence 
in patients with CLL. In the abovementioned data concerning serotype distribution 
of IPD in patients with hematological malignancy, serotypes 14 and 6B were the 
most common serotypes. The high persistence seen for serotype 14 offers support 
to the recommendation of early PCV administration to CLL patients. The decline in 
the serotype 6B antibody concentration to levels below the baseline may indicate a 
necessity of a booster vaccination. 
6.4 Role of the polysaccharide booster vaccine 
Earlier data concerning the antibody response of pneumococcal booster vaccine 
after conjugate vaccine was not available in CLL patients. It has been shown that 
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patients with Hodgkin’s lymphoma and HSCT recipients benefit from a PCV primer 
before PPV23 (Chan et al. 1996; Cordonnier et al. 2009; Cordonnier et al. 2010). In 
our study, this booster effect was not observed in CLL patients. While PPV23 given 
one year after PCV13 improved PCV13 immunogenicity in adults with HIV, it had 
a negative effect on immunological memory induced by PCV13, causing 
hyporesponsiveness, thereby leading to the depletion of memory B-cells (Farmaki et 
al. 2018). Similar observations concerning depletion of immunological memory 
following PPV23 given after PCV have been reported (Papadatou & Spoulou 2016). 
Our study design was based on a long interval between vaccinations as this practice 
has been thought to decrease hyporesponsiveness, potentially providing better 
immunogenicity (Kobayashi et al. 2015). However, our data suggest that PCV is not 
capable of inducing properly functional memory B–cells in CLL patients. One 
probable reason for a poor antibody response with PPV23 after the PCV primer is 
abnormalities in both B- and T –cell functions even at an early stage of CLL, leading 
to the inadequate immunogenicity of conjugate vaccines (Dearden 2008; Morrison 
2010; Pasiarski et al. 2014). 
6.5 Limitations of the study and future perspectives 
This study has some limitations. In study I, IDO expression was analyzed only in 
PBMCs but not in stromal cells to confirm IDO expression in a microenvironment. 
Furthermore, more far-reaching interpretation of data would have required analysis 
of functional Treg cells to confirm the formation of Treg cells as a result of increased 
IDO activation in CLL patients. These aspects should be verified in further studies 
as our knowledge of impact of IDO on tumor immunotolerance has broadened and 
research methods have evolved since our study period. 
 In study II, the pneumococcal vaccination status was not known, but based on 
a national survey in Finland the uptake of pneumococcal vaccines in the high-risk 
groups has been low (Ruutu et al. 2004). Furthermore, the study was performed in 
patients with hematological malignancies before the introduction of PCVs currently 
in use. As stated above, herd immunity may influence IPD serotype distribution to 
a lesser extent in patients with hematological malignancy. Hence, our results may 
reflect serotype distribution also in the era of PCVs. However, these data need to be 
confirmed in a patient population compiled after the introduction of PCVs. 
In studies III and IV, the number of subjects remained quite small due to the 
relative rarity of the disease and the natural course of CLL. Since the study, PCV7 
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has been replaced with PCV13, but the data should be comparable due to the same 
carrier protein, CRM (Pichichero 2013). Furthermore, PCV13 has also been shown 
to generate suboptimal responses in CLL patients (Pasiarski et al. 2014). Still, more 
studies with the PCV13 primer are warranted in patients with CLL. Whether CLL 
patients would benefit from a PCV13 booster instead of PPV23 also needs to be 
studied. 
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7 SUMMARY AND CONCLUSIONS 
Patients with hematological malignancies are at a high risk for IPD. Morbidity and 
mortality of IPD have remained significant in this group of patients even in the era 
of PCVs. Also, the uptake of pneumococcal vaccines is still inadequate within this 
patient group. CLL patients in particular have profound disturbances in 
immunoregulatory functions and the efficacy of pneumococcal vaccines has been 
limited. Due to the lack of comprehensive data, the optimal vaccination strategies 
are still unclear. 
The IDO enzyme suppresses T cell functions and increased IDO activation and 
expression have been shown in malignant disease. IDO may contribute to the 
induction of tolerance to tumor cells and the occurrence of disturbances in immune 
functions. In CLL patients, the role of the IDO has not been previously studied. 
In this study, the main objectives were to assess the incidence rate and serotype 
distribution of IPD and the serotype coverage of pneumococcal vaccines in patients 
with hematological malignancy. In CLL patients, we studied the persistence of PCV- 
induced antibody responses and the efficacy of the PPV23 booster vaccine. 
Furthermore, IDO activation and expression and their possible impact on vaccine 
responses in CLL patients were evaluated. 
 
The main findings and conclusions in studies I to IV were: 
1. IDO activity was increased in patients with CLL. However, IDO expression 
 in malignant B-cells was reduced reflecting increased IDO activity arising 
 from stromal cells. Influence of increased IDO activity on PCV7 antibody 
 was not observed. Increased IDO activity may have a role in 
 interactions between CLL cells and the microenvironment but these findings 
 require further studies. 
2. Before the use of PCVs, the risk of IPD in Finnish patients with 
 hematological malignancies was clearly higher than that seen in the general 
 population. Serotype  distribution also seemed to differ from the 
 distribution in the general population.  Furthermore, serotype coverage of 
 pneumococcal vaccines was lower in patients with hematological 
 malignancies. These findings indicate that the predisposition to IPD in these 
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 patients still remains high. To confirm these results, studies covering the 
 PCV era are warranted. 
3. After PCV7, the antibody concentrations remained at a level considered to 
 be protective against IPD for four out of seven serotypes in more than 50% 
 of the CLL patients for at least five years. There were no statistically 
 significant differences in antibody concentrations between CLL patients and 
 controls over this period, but a trend toward lower concentrations was seen 
 in CLL  patients for six serotypes. 
4. The efficacy of a PPV23 dose given five years after PCV7 in CLL patients 
 did not seem to be sufficient to induce an antibody response suggested to 
 be protective against IPD. Future studies are still warranted to identify an 
 optimal pneumococcal vaccination strategy in this high-risk patient 
 population. 
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Abstract
Indoleamine 2,3-dioxygenase (IDO) activity and expression is increased in many hematological malignancies,
but has not been previously studied in chronic lymphocytic leukemia (CLL). We determined IDO activity and
expression in 49 patients with CLL. We found that IDO activity is increased in CLL. This may have some
inﬂuence on CLL progression.
Background: Indoleamine 2,3-dioxygenase (IDO) is an enzyme involved in the catabolism of tryptophan, suppressing
T-cell activity. IDO activity and expression are increased in many malignant diseases, including hematological
malignancies. IDO expression can mediate immunotolerance to tumors. IDO activity and expression have not
previously been studied in chronic lymphocytic leukemia (CLL). Methods: We measured IDO activity by calculating
the kynurenine-tryptophan (kyn-trp) ratio. IDO and IDO2 gene expression was determined by using real-time poly-
merase chain reaction (PCR). Results: In patients with CLL, the serum kyn-trp ratio—reﬂecting increased IDO
activity—was signiﬁcantly higher compared with controls, but in peripheral blood mononuclear cells (PBMCs)—
mainly representing malignant B cells—the expression of genes encoding IDO and IDO2 enzymes was reduced.
Conclusions: Increased IDO activity in patients with CLL may affect disease progression, although it originates from
cells other than malignant B cells.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 5, 363-65 © 2012 Elsevier Inc. All rights reserved.
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Introduction
Chronic lymphocytic leukemia (CLL) is an incurable malignancy
of mature B-cell lymphocytes.1 The disease is associated with com-
plex immunodeﬁciency, patients evincing defects in B- and T-cell
function and antigen presentation as well as hypogammaglobuline-
mia and poor response to vaccines.2-5
Indoleamine 2,3-dioxygenase (IDO) is a key enzyme in trypto-
phan metabolism and catalyzes the initial rate-limiting step of tryp-
tophan degradation along the kynurenine pathway.6 Its activity can
thus be estimated indirectly by determining the ratio of its metabolite
and substrate (ie, the kynurenine-tryptophan [kyn-trp] ratio). The
IDO enzyme is encoded by the gene INDO, which is located in the
short arm of human chromosome 8 (8p12-p11).7 IDO2 has recently
been reported and it bears structural similarity to IDO and its enzy-
matic activity, but with lower efﬁcacy.8 IDO2 is encoded by the gene
INDOL1, which is located on chromosome 8p12 immediately
downstream of the gene INDO.9 IDO induces peripheral immuno-
tolerance and immunosuppression by reducing the local concentra-
tion of tryptophan and suppressing T-cell proliferation and activa-
tion. IDO is expressed in many cells, including antigen-presenting
cells,10,11 whereas lymphoid cells rarely express it under physiologic
conditions.12 In a recent study in mice, a relationship between B cells
and dendritic cells capable of expressing IDO in response to inter-
ferons was demonstrated.13 In human adult T-cell leukemia/lym-
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phoma14 and acute myeloid leukemia (AML),15 malignant cells ex-
press IDO. Manipulation of IDO expression has recently been
observed to be a promising treatment option in inﬂammatory and
autoimmune syndromes, cancer, and transplantation.12
The aim of this study was to determine IDO activity and its gene
expression in CLL cells. Further, the signiﬁcance of IDO activity as a
possible cause of the immunodeﬁciency state prevailing in CLL—
predisposing to infections and leading to impaired vaccination re-
sponses—was assessed.
Materials and Methods
The study population for IDO activity measurements comprised
49 patients with CLL and 24 age- and sex-matched controls from
Tampere and Turku University Hospitals who had participated in
our pneumococcal vaccine response study. All patients had the B-cell
phenotype, and the disease stage according to the Binet classiﬁcation
was A in 39 patients, B in 9 patients, and C in 1 patients. Eleven
patients had received chemotherapy.5 Venous blood samples for
IDO measurements had been taken before vaccination. Tryptophan
(mmol/L) and kynurenine (mol/L) concentrations in peripheral
blood were measured by reverse-phase high-performance liquid
chromatography. Tryptophan was separated with a Shimadzu liquid
chromatograph LC-10AD VP (Shimadzu Co, Kyoto, Japan) using a
50-mmBDSHypersil C18 5-mcolumn (Thermo Fisher Scientiﬁc,
Waltham, MA). It was monitored by ﬂuorescence with a Shimadzu
RF-10A XL (Shimadzu Co) detector at 266-nm excitation and
366-nm emission wavelengths. Kynurenine was separated with a
Hewlett-Packard 1100 liquid chromatograph (Hewlett-Packard Co,
Palo Alto, CA) using a Merck LiChroCART 55- to 4150-mm car-
tridge containing a Purospher STAR RP-18 3-m column (Merck
& Co, Darmstadt, Germany). It was determined by ultraviolet ab-
sorption at 360-nm wavelength with a Hewlett-Packard G13144
detector. The kyn-trp (mol/mmol) ratio was calculated by relating
concentrations of kynurenine to tryptophan, allowing estimation of
IDO activity. TheMann-WhitneyU test was applied in comparisons
of kynurenine and tryptophan concentrations and the kyn-trp ratio.
Correlations were calculated by the Spearman rank correlation test.
INDO (encoding IDO enzyme) and INDOL1 (IDO2) gene ex-
pression was studied in 10 patients with CLL and in 7 controls. The
disease stage according to the Binet classiﬁcation was A in all 10
patients. The blood samples were subjected directly to leukocyte
separation with a Ficoll-Paque density gradient (Ficoll-Paque
PREMIUM, catalogue No. 17-5442-02, General Electric Health-
care Bio-Sciences, Uppsala, Sweden). The peripheral blood mono-
nuclear cell (PBMC) layer was collected and the cells were suspended
in 1 mL of RPMI-1640 medium (catalogue No. R0883, Sigma-
Aldrich, St. Louis, MO). Immediately after PBMC separation, traces of
erythrocytes were lysed with 10 seconds of H2O treatment and recov-
ered with 0.9% NaCl. Total RNA extraction was performed with the
QiagenRNeasyMidiKit (catalogueNo. 75144,Qiagen,Valencia,CA).
The RNA (500 ng) was converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (catalogue No. 4368814, Applied
Biosystems, Carlsbad, CA). The isolated RNA was quantiﬁed spectro-
photometrically (NanoDrop, Thermo Scientiﬁc, Waltham, MA) and
tested for inhibition to achieve the correct RNA load for cDNA
conversion. Levels of gene transcripts were determined byTaqMan real-
time PCR.We analyzed the levels of the IDOand IDO2 transcript with
a separate single IDO gene expression assay (catalogue No.
Hs00158027_m1, Applied Biosystems) and an IDO2 gene expres-
sion assay (catalogue No. Hs00401201_m1, Applied Biosystems)
and TaqMan real-time PCR. The gene expression results were ana-
lyzed with relative quantiﬁcation (RQ) documents and the RQMan-
ager software for automated data analysis (Applied Biosystems). The
endogenous control for transcript was-actin (BACT, catalogueNo.
Hs03023880_g1). The calculations were based on average (Ct)
values obtained by subtracting the cycle threshold (Ct) value of the
endogenous control from that of the given target gene. Next, the
Ct values were calculated by subtracting theCt of the calibrator
from the Ct value of both target genes. The RQ value, which desig-
nates the fold change for both targets, was derived from the formula:
RQ 2Ct. A gene that was regulated 2-fold ( 2.0 or 0.5)
was considered to be signiﬁcantly regulated.16
Results and Discussion
Kynurenine and tryptophan concentrations and their ratio (kyn-
trp) and INDO (IDO) and INDOL1 (IDO2) gene RNA expressions
in PMBCs in patients with CLL and controls are shown in Table 1.
The kyn-trp ratio, reﬂecting increased IDO activity, was signiﬁcantly
higher in patients with CLL than in controls. However, no statisti-
cally signiﬁcant difference in kynurenine or tryptophan concentra-
tions was detected between patients and controls.
The association of the kyn-trp ratio was calculated against several
demographic and disease-associated parameters in patients with CLL,
including age; sex; disease duration; Binet class; IgG, IgM, and IgA
subclasses; blood cell counts (lymphocytes, neutrophils, thrombocytes);
and hemoglobin and C-reactive protein levels. The cytomegalovirus
(CMV) status or known prognostic markers were not available. A statis-
tically signiﬁcant association was detected only with age (r .367; P
.010; in controls, P .949) and disease duration (r .290; P .044),
but not, eg,withBinet class (A vs. B orC;P .130). In a previous study,
Table 1 Kynurenine and Tryptophan Concentrations and
Their Ratio (kyn-trp) and INDO and INDOL1 (IDO2)
Gene RNA Expression in PBMCs in Patients With
CLL and Controlsa
Character CLLn  49
Controls
n  24
P
Value
Kyn-Trp Ratio,
mol/mmol 37 (31-48) 33 (29-38) .027
Kynurenine,
mol/L 3.6 (2.7-4.6) 3.1 (2.6-3.8) .260
Tryptophan,
mmol/L 0.094 (0.083-0.107) 0.095 (0.083-0.112) .425
n 10 n 7 RQ
INDO (IDO),
av Ct 14.18 11.63 .17
INDOL1 (IDO2),
av Ct 15.36 12.26 .12
Abbreviations: av Ct  average (mean)  threshold cycles; CLL  chronic lymphocytic leu-
kemia; IDO  indoleamine 2,3-dioxygenase; PBMCs  peripheral blood mononuclear cells;
RQ relative quantiﬁcation.
a Results Are expressed in medians (quartiles) if not otherwise stated.
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the level of IDO activity was higher in the plasma of the nonagenarians
comparedwith young controls.17Wealso evaluated thepossible effect of
IDO activity on the vaccine response to a 7-valent pneumococcal con-
jugate vaccine.5 There was no difference in kyn-trp between vaccine
responders and nonresponders among patients with CLL, and no sig-
niﬁcant correlations between the kyn-trp ratio and serotype-speciﬁc re-
sponses were detected.
In the gene expression section of the study, we observed a signiﬁ-
cantly reduced expression of the INDO (encoding IDO enzyme) and
INDOL1 (IDO2) genes in PMBCs,mainly representingmalignant B
cells in patients with CLL (Table 1), which is in contrast to ﬁndings
of increased IDO expression in some other hematologic malignan-
cies.14,15 In recent studies, it has been shown that treatment with che-
motherapy decreases IDO activity and expression.18,19 In our study
population, the majority had never received any treatment for CLL. In
T-cell/histiocyte-rich large B-cell lymphoma, IDO production may be
involved in the poor prognosis of the disease in that IDO can render the
microenvironment tolerogenic to the tumor cells.20Patients with AML
and a higher kyn-trp ratio have lower survival.15 Our ﬁndings would
indicate that the increased kyn-trp ratio in patients with CLL—reﬂecting
increased IDOactivity—originates fromcells other thanPBMCsormalig-
nant B lymphocytes. Mesenchymal stromal cells could be responsible for
increased IDO activity, and this type of cell can also expresses IDO.21 In-
creased IDOactivitymay contribute to disease progression, eg, by suppress-
ing cell-mediated immunity. It also may take part in interactions between
CLL and stromal cells in the CLLmicroenvironment.
IDO-expressing dendritic cells are involved in the generation of
CD4CD25FoxP3 regulatory T cells, which are critical regula-
tors of adaptive immunity.22 The regulatory T-cell number is in-
creased in patients with CLL.23 Whether this increased IDO activity
has a role in the promotion of regulatory T cells and in the complex
immunodeﬁciency in CLL—predisposing to infections and leading
to impaired vaccination responses—requires further study. Accord-
ing to our ﬁndings, the cells responsible for increased IDO activity in
CLL are not malignant B cells.
Clinical Practice Points
● The IDO enzyme is expressed in many cancer cells. IDO can
contribute to immunotolerance to tumors.
● To our knowledge, this is the ﬁrst study to report IDO activity and
expression in CLL. We found increased IDO activity in patients
with CLL.
● In the future, IDO inhibitors might be effective antitumor agents.
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ABSTRACT
The baseline national invasive pneumococcal disease (IPD) incidence rate, serotype distribution and
serotype coverage of pneumococcal vaccines were evaluated in patients with Hodgkin’s and non-
Hodgkin’s lymphomas, myeloma and leukaemia within 1 year after haematological diagnosis
during 1995–2002, before introduction of pneumococcal conjugate vaccines. Pneumococcal
serotype distribution among these patients was different from serotypes causing IPD in the general
population. The serotype coverages of PCV13 and PPSV23 were 57% and 64%, respectively, lower
than in the general population. This reflects a higher predisposition to IPD in vaccinated patients
with haematological malignancies and possibly less benefit of herd immunity gained with the wide
use of pneumococcal conjugate vaccines in the general population. This data will be useful as a
baseline for determining the future role of adult PCV vaccination in these patient groups.
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Introduction
Patients with immunocompromising conditions such as haem-
atological malignancies are at the highest risk for invasive
pneumococcal disease (IPD)[1] However, only limited popula-
tion-based data are available concerning incidence and sero-
type distribution in these patients. According to a previous
study, the overall incidence of IPD in adults with haemato-
logical malignancies in Finland was estimated to be 5.5/1000
per year, when population at risk in person years were used as
denominators for these malignancies. This is 50-times higher
than in the background population.[2]
The antibody responses to pneumococcal vaccines are
limited in patients with haematological malignancies.[3–6] In a
study with chronic lymphocytic leukaemia (CLL) patients, no
antibody responses were detected after a single dose of
PPSV23 [3], but 24% of the patients achieved a significant
response (defined as an at least 2-fold increase and a post-
vaccination concentration of at least 0.35 mg/ml) after a single
dose of 7-valent pneumococcal conjugate vaccine (PCV7).[4]
Furthermore, a retrospective study with myeloma patients
showed that, after a single dose of 23-valent pneumococcal
polysaccharide vaccine (PPSV23), only 33% of the patients
achieved a significant antibody response defined as a geo-
metric mean antibody titer above 25 units or above 40 units
with more than one of the six specific antibody titers below 25
units.[5] After allogeneic stem cell transplantation the response
rate to three doses of PCV7 was 79%, but the antibody
response was transient.[6]
The serotypes included in pneumococcal vaccines were
selected on the basis of serotypes causing IPD in children. The
pneumococcal conjugate vaccines PCV10 and PCV13 contain
10 and 13 of these serotypes.[7] The investigational 15-valent
pneumococcal conjugate vaccine (PCV15) has expanded
coverage for serotypes 22F and 33F.[8] PCVs are thought to
be more immunogenic depending on serotype or age when
compared to PPSV23 and they also prevent IPD through an
indirect effect, i.e. herd immunity.[9] Since September 2010
PCV10 has been included in the Finnish childhood vaccination
programme with a 2 + 1 schedule. During the first 3 years the
PCV10 uptake was estimated at 95% and the overall IPD rate
among vaccine-eligible children was reduced by 80%.[10]
PCV13 and PPSV23 have recently been included in the Finnish
national vaccination programme for patients who have
received haematopoietic stem cell transplantation (HSCT).
We evaluated the incidence of IPD, serotype distribution of
the pathogens and serotype coverage of PCV7, PCV10, PCV13
and PPSV23 in patients with specific haematological malig-
nancies (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma,
myeloma and leukaemia) within 1 year after haematological
diagnosis in a registry-based national study in Finland during
1995–2002, before the start of the routine infant conjugate
vaccine programme.
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 2015 Society for Scandinavian Journal of Infectious Diseases
Materials and methods
All clinical microbiology laboratories in Finland report invasive
pneumococcal isolates to the National Infectious Disease
Register (NIDR), a population-based laboratory surveillance
system. A case of IPD was defined as isolation of S.pneumoniae
from blood and/or CSF during 1995–2002. S.pneumoniae
isolates were serotyped at the National Public Health
Institute (KTL) reference laboratory by counter-immunoelectro-
phoresis or latex agglutination using pneumococcal anti-
sera.[11] Pneumococcal serotypes were grouped as follows:
7-valent PCV types (4, 6B, 9V, 14, 18C, 19F, 23F), 10-valent PCV
types (adding serotypes 1, 5 and 7F), 13-valent PCV types
(adding serotypes 3, 6A and 19A), 23-valent PPSV types (1, 2, 3,
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F,
20, 22F, 23F and 33F) and all other types.
National IPD surveillance data were linked to the Finnish
Cancer Registry database [12] to obtain information regarding
diagnosis of haematological malignancy (Hodgkin’s lymph-
oma, non-Hodgkin’s lymphoma, myeloma and leukaemia)
within 1 year before the first positive culture.[2] In addition,
ICD (9th and 10th Revision) codes of haematological malignancy
for the IPD episode were collected from the National Hospital
Discharge Register (HILMO). To maintain the cumulative
incidence of haematological malignancies stable, only diag-
nosed diseases within 1 year before the first episode of IPD
were analysed.
Incidence rates of IPD in patients with haematological
malignancy including 95% confidence intervals were calculated
using person-time of patients with a specific haematological
malignancy in the Cancer Registry as a denominator. Data were
analysed using SPSS Statistics 21.0 (Chicago, IL).
National registry data use was authorised by the Ministry of
Social Affairs and Health, the Finnish Data Protection Authority
and the National Research and Development Centre for
Welfare and Health.
Results
Among 4357 cases of IPD identified during 1995–2002,[2] a
haematological malignancy (Hodgkin’s or non-Hodgkin’s
lymphoma, myeloma or leukaemia) had been diagnosed in
56 (1.3%) cases within 1 year before the IPD episode. From
these 56 IPD cases, the isolates were available for serotyping in
47 cases (84%). The median age of these patients was 64 years
(range¼ 9 months–81 years) at the time of IPD and 32 isolates
(68%) were from males. In 45 cases (96%), bacteria were
isolated from blood and in two cases from CSF (4%).
The overall incidence rate of IPD in patients with haemato-
logical malignancy was 3.8 per 1000 person-years (Table 1).
Patients with myeloma had the highest rate of IPD (10.9 cases
per 1000 person-years). The most common serotypes were 14
in eight IPD episodes, 6B in five, 11A and 4 in three each and
19F in one (Figure 1). Of the isolates, 47% (22/47), 51% (24/47),
57% (27/47) and 64% (30/47) were serotypes included in PCV7,
PCV10, PCV13 and PPSV23, respectively; 32% (15/47) of the
isolates were not included in either PPSV23 or PCV13. PCV15
would have yielded serotype coverage for 29 cases (62%).
Serotype coverage varied with the type of haematological
malignancy. In patients with myeloma the serotypes included
in PCV13 and PPSV23 covered 12 (60%) and 14 (70%) cases,
respectively (Figure 2).
Discussion
Few population-based studies concerning IPD incidence are
available in patients with haematological malignancies. Our
data indicates that the risk of IPD in these patients was
35-times higher than in the general population in Finland,
where the average annual incidence of IPD was 0.11 cases per
1000 persons.[2] The highest rates were seen in patients with
myeloma, consistent with a previous report.[13]
Pneumococcal serotype distribution in patients with haem-
atological malignancies before introduction of the infant
conjugate vaccine programme was different from serotypes
causing IPD among the general population, where the most
common serotypes in the general adult population were 4, 14,
3, 7F and 23F and in children serotypes 6B, 14, 19A, 18C and
7F.[11] In a European Bone Marrow Transplantation (EBMT)
survey the identified serotypes in IPD following stem cell
transplantation were 23F, 6, 14, 9, 11 and 22, but only 33% of
isolates had been serotyped.[14] In Spain serotypes 6A, 23F,
11A and 33F were more frequently found in immunocom-
promised patients. Serotype 6A was independently related to
haematological malignancies.[15] All the most common sero-
types in our study are included in PPSV23, but serotype 11A is
not covered in PCV13. In an earlier study the serotype coverage
of PCV13 and PPSV23 in the general population above 18 years
was 75% and 83%, respectively,[11] which is 1.3-times higher
than in the patients in this study. The serotype coverages in
haematological and haematopoietic stem cell transplant
patients in France (i.e. PCV13, 84%; PPSV23, 92%) [16] were
also 1.5- and 1.4-times higher than in our study, respectively.
Thus, the proportion of serotypes which was not covered in
PPSV23 and PCV13 was relatively high in our study.
There are some limitations in our study. The data was
collected during the years 1995–2002, before the pneumococ-
cal conjugate vaccine era and possible herd immunity from
infant PCV vaccination. In the US, rates of IPD in adults with
HIV-infection, another important group of immunocomprom-
ised patients, decreased from 399 to 298 per 100 000 (25%) 7
years after PCV7 introduction, whereas rates of non-PCV7
serotypes increased from 168 to 269 per 100 000 (60%).[17]
In Finland, after PCV10 was introduced into the national
Table 1. Rates of invasive pneumococcal disease (IPD) in patients with
haematological malignancies in Finland during 1995–2002 within 1 year of
haematological diagnosis.
Malignancy
Cases of specified
malignancy
(person years)a
IPD cases
with specified
malignancy
Incidence rate/1000
person years
(95% CI)
Myeloma 2 393 26 11 (7.4–16)
Leukaemiab 4 201 17 4.1 (2.5–6.5)
Non-Hodgkin’s lymphoma 7 131 12 1.7 (1.0–3.0)
Hodgkin’s lymphoma 1 080 1 0.9 (0.1–6.6)
Total 14 805 56 3.8 (2.9–4.9)
aFrom the Finnish Cancer Registry.
bAcute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic
lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML).
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vaccination programme, during the first 3 years non-PCV10
serotypes increased marginally from 0.03 to 0.06 cases per
1000 person-years.[10] Furthermore, the ICD codes collected
from the registry and HILMO may have been incomplete and
some diagnoses may have been missed, although the Finnish
Cancer Registry has a large coverage. Also, the pneumococcal
vaccination status was not known, but a national survey in
Finland found that, in the high risk groups, the number of
patients vaccinated with PPSV23 was low.[18] The number
of HSCT recipients was not known, but the proportion of
vaccinated HSCT recipients was estimated to be relatively
low, because only haematological malignancies diagnosed
within 1 year before the first episode of IPD were included in
the data.
Our data indicates that the baseline pre-PCV serotype distri-
bution of IPD in patients with haematological malignancies
was different from that in the general population. Serotype
coverage of both PCV13 and PPSV23 was 20% lower in this
group. These findings suggest that pre-disposition to IPD is still
high in vaccinated patients. These data will be useful as a
baseline for evaluating the potential indirect effects of the
infant PCV10 vaccination programme on patients with haem-
atological malignancies in Finland. They will also be helpful in
determining the future role of adult PCV vaccination of these
high risk patients. Because of the possible different serotype
distribution and lower serotype coverage, the potential bene-
fits from herd immunity may be low and protection of patients
with haematological malignancies might require new
approaches to vaccination, such as protein-based vaccines
[19] and pneumococcal conjugate vaccines with expanded
serotype coverage (e.g. PCV15).[8] Further studies during the
conjugate vaccine era are warranted to confirm these data.
Included in 
PCV7
PCV10
PCV13
non PCV 
0
1
2
3
4
N
um
be
r 
of
 s
tr
ai
ns
4 6B 14 19
F
18
C
23
F 7F 6A 19
A 8 9N 11
A
22
F 11 15 16 18
B
19
F,
 6
A
23
A 3331
Myeloma
Leukaemia
Non-Hodgkin’s lymphoma
Hodgkin’s lymphoma
35 35
F 41
Figure 1. Distribution of pneumococcal serotypes in patients with haematological malignancies in Finland during 1995–2002 within 1 year of diagnosis.
0
2
4
6
8
10
12
14
16
Hodgkin´s lymphoma
n=1
Myeloma n=20 Any leukaemia n=15 Non-Hodgkin’s
lymphoma n=11
N
um
be
r o
f s
er
ot
yp
es
 in
cl
ud
ed
 in
 v
ac
ci
ne
s PCV7 PCV10 PCV13 PPSV23 non-PCV13/non-PPSV23
Figure 2. Serotype coverage by pneumococcal vaccines in patients with haematological malignancies in Finland during 1995–2002 within 1 year of diagnosis.
INFECTIOUS DISEASES 401
Disclosure statement
The authors report no conflicts of interest. The authors alone
are responsible for the content and writing of the paper.
References
[1] Kyaw MH, Rose CE , Fry AM, et al. The influence of chronic illnesses
on the incidence of invasive pneumococcal disease in adults. J Infect
Dis. 2005;192:377–386.
[2] Klemets P, Lyytika¨inen O, Ruutu P, et al. Invasive pneumococcal
infections among persons with and without underlying medical
conditions: implications for prevention strategies. BMC Infect Dis.
2008;8:96.
[3] Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination
against different types of antigens in patients with chronic
lymphocytic leukaemia. Br J Haematol. 2001;114:107–110.
[4] Sinisalo M, Vilpo J, Ita¨la¨ M, et al. Antibody response to 7-valent
conjugated pneumococcal vaccine in patients with chronic
lymphocytic leukaemia. Vaccine. 2007;26:82–87.
[5] Hinge M, Ingels HA, Slotved HC, Mølle I. Serologic response to a
23-valent pneumococcal vaccine administered prior to autologous
stem cell transplantation in patients with multiple myeloma. APMIS.
2012;120:935–940.
[6] Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early
versus late immunization with pneumococcal conjugate vaccine
after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:
1392–1401.
[7] Rodgers GL, Klugman KP. The future of pneumococcal disease
prevention. Vaccine. 2011;29(Suppl 3):S43–S48.
[8] Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of
a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197)
in an infant-rhesus monkey immunogenicity model. Vaccine.
2011;29:8870–8876.
[9] Pulido M, Sorvillo F. Declining invasive pneumococcal disease
mortality in the United States, 1990-2005. Vaccine. 2010;28:889–892.
[10] Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent
pneumococcal conjugate vaccination on invasive pneumococcal
disease in Finnish children - a population-based study. PLoS One.
2015;10:e0120290.
[11] Klemets P, Lyytika¨inen O, Ruutu P, et al. Trends and geographical
variation in invasive pneumococcal infections in Finland. Scand J
Infect Dis. 2008;40:621–628.
[12] Brenner H, Hakulinen T. Reduction in selective under-ascertainment
bias in population-based estimates of cancer patient survival by age
adjustment. Eur J Cancer. 2005;41:1788–1793.
[13] Wong A, Marrie TJ, Garg S, et al. SPAT Group. Increased risk of
invasive pneumococcal disease in haematological and solid-organ
malignancies. Epidemiol Infect. 2010;138:1804–1810.
[14] Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive
pneumococcal infection following stem cell transplantation: a
European Bone Marrow Transplantation survey. Br J Haematol.
2002;117:444–450.
[15] Luja´n M, Burgos J, Gallego M, et al. Effects of immunocompromise
and comorbidities on pneumococcal serotypes causing invasive
respiratory infection in adults: implication for vaccine strategies.
Clin Infect Dis. 2013;57:1722–1730.
[16] Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive
Streptococcus pneumoniae infections in onco-haematology and
haematopoietic stem cell transplant patients in France. Are the
serotypes covered by the available anti-pneumococcal vaccines?
Clin Microbiol Infect. 2009;15:865–868.
[17] Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive
pneumococcal disease among HIV-infected adults in the era of
childhood pneumococcal immunization. AIDS. 2010;2253–2262.
[18] Ruutu P, Kuusi M, Nuorti PJ, Koskinen, S. Communicable diseases.
In: Aromaa A, Koskinen S, editors. Health and functional capacity
in Finland: baseline results of the Health 2000 examination survey.
Helsinki: National Public Health Institute, 2004. pp 67–69.
[19] Olaya-Abril A, Jime´nez-Munguı´a I, Go´mez-Gasco´n L, et al.
Identification of potential new protein vaccine candidates through
pan-surfomic analysis of pneumococcal clinical isolates from adults.
PLoS One. 2013;8:e70365.
402 V. LINDSTRO¨M ET AL.
 PUBLICATION 
III 
Antibody persistence after pneumococcal conjugate vaccination in patients 
with chronic lymphocytic leukemia 
Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, Itälä-Remes M, 
Sinisalo M 
Human Vaccines & Immunotherapeutics 2018;14(6):1471-1474 
https://doi.org/10.1080/21645515.2018.1436424 
 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
 
 
SHORT REPORT
Antibody persistence after pneumococcal conjugate vaccination in patients
with chronic lymphocytic leukemia
Vesa Lindstr€om a, Janne Aittoniemib, Urpu Salmenniemic, Helena K€ayhtyd, Heini Huhtalae, Maija It€al€a-Remesf,
and Marjatta Sinisalog
aDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; bDepartment of Clinical Microbiology,
Fimlab Laboratories, Tampere, Finland; cDepartment of Hematology and Stem Cell Transplantation Unit, Division of Medicine, Turku University
Hospital, Turku, Finland; dDepartment of Health Security, National Institute for Health and Welfare, Helsinki, Finland; eFaculty of Social Sciences,
University of Tampere, Tampere, Finland; fDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, HUS, Helsinki,
Finland; gDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland
ARTICLE HISTORY
Received 7 November 2017
Revised 13 January 2018
Accepted 29 January 2018
ABSTRACT
Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus
pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a signiﬁcant antibody response for
some CLL patients. In this study we investigated antibody persistence after PCV7 in patients with CLL. The
study material comprised 24 patients with CLL and 8 immunocompetent controls. The median antibody
concentrations ﬁve years after PCV7 were lower for six pneumococcal serotypes in patients with CLL
compared to controls, but the difference was not statistically signiﬁcant. Depending on the serotype, the
percentage of the CLL patients with antibody levels suggested to provide protection against invasive
pneumococcal disease (IPD) varied from 29 to 71% ﬁve years after vaccination. This data suggests that
PCV could result in antibody persistence at least ﬁve years in CLL patients.
KEYWORDS
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Chronic lymphocytic leukemia (CLL), a mature B-cell neoplasm,
is the most common type of leukemia in adult Caucasians.1 CLL
is associated with a signiﬁcant dysfunction of the immune system
that results in both quantitative and qualitative defects in innate
and adaptive immune responses.2 While hypogammaglobuline-
mia can occur even in the early stage of disease, it usually becomes
more severe during the course of the disease and at more
advanced stages.3 Infections are the most common cause of mor-
tality in CLL patients. The majority of infections are bacterial,
caused by common organisms, including Streptococcus pneumo-
niae, Staphylococcus aureus andHaemophilus inﬂuenzae.4
Previous studies with the 23-valent pneumococcal polysac-
charide vaccine (PPV23) in patients with CLL demonstrated no
antibody responses at all or only weak responses.5-8 In contrast,
the immunogenicity of pneumococcal conjugate vaccine (PCV)
in patients with CLL has been shown in a few earlier studies. A
single dose of 7-valent pneumococcal conjugate vaccine
(PCV7) given at an early stage of the CLL resulted in a signiﬁ-
cant response in almost 40% of patients.9 Furthermore, 13-val-
ent pneumococcal conjugate vaccine (PCV13) induced at least
a two-fold increase in antibody titers from baseline in 58% of
previously untreated CLL patients, but an antibody concentra-
tion of 0.35 mg/ml was not used as a serological threshold for
adequate response.10 Many current international guidelines
recommend PCV13 for immunocompromised patients. The
persistence of pneumococcal antibodies in patients with CLL
has yet to be studied.
In this follow-up study, pneumococcal antibody persistence
was assessed in CLL patients and immunocompetent controls
at ﬁve years after one dose of PCV7 given as part of an earlier
response study.9
The study population comprised 24 patients with CLL (12
males and 12 females), with a median age of 64 years (range
47–86 years) from Tampere and Turku University Hospitals.
The control population comprised 8 subjects (median age
67 years, range 57–82 years, 4 males and 4 females) without
any known immunological or hematological defects from Tam-
pere University Hospital. The patients and control subjects had
participated in an earlier pneumococcal vaccine response study
with PCV7.9
An informed consent to participate was obtained from all
patients and controls. The study was approved by the ethical
board of the Pirkanmaa Hospital District and the trial was reg-
istered at http://ClinicalTrials.gov (NCT00919321).
Clinical and laboratory characteristics of the CLL patients
are shown in Table 1. The disease status according to Binet
classiﬁcation was A (early stage of the disease) in 16, B
(intermediate) in 2, and C (advanced stage) in 6 patients. A
total of 16 patients had never been treated for CLL. Seven
patients had suffered from severe infections (needing intrave-
nous antibiotics or hospitalization) and six patients from mild
to moderate infections (treated with oral antibiotics) during the
ﬁve years since PCV7 vaccination. Only one of these infections
was pneumococcal infection, i.e. pneumococcal septicemia.
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Hypogammaglobulinemia (S-IgG <6.77 g/l) was detected in 11
patients.
The concentrations of serum IgG antibody against pneumo-
coccal capsular polysaccharides were measured by a modiﬁca-
tion of the 22F inhibition enzyme immunoassay (EIA) method
as previously described.11 An antibody concentration of
0.35 mg/ml was considered as a threshold for protection against
invasive pneumococcal disease (IPD), as recommended by
World Health Organization WHO.12 A comparison of antibody
concentrations between CLL patients and controls was per-
formed with Fishers exact test.
Pneumococcal antibody concentrations four weeks and ﬁve
years after the administration of PCV7 are shown in Table 2. In
the CLL patients, median antibody concentrations against
pneumococcal serotypes 4, 6B, 18C and 19F after ﬁve years
were approximately 50% lower than those measured four weeks
after vaccination. Furthermore, antibody concentrations
against serotypes 9V and 23F were approximately 75% and
65% lower ﬁve years after vaccination, respectively. In contrast,
the median concentration of the antibody against serotype 14
remained at a similar level over the ﬁve-year period following
the vaccination. No statistically signiﬁcant differences were
seen in antibody concentrations between CLL patients and con-
trols ﬁve years from vaccination. The pneumococcal antibody
concentrations in controls declined by more than 50% in each
serotype group. The median concentration of the antibody
against serotype 9V was 95% lower in controls, as measured
ﬁve years after the administration of PCV7.
The percentages of subjects whose antibody concentrations
were at a level suggested to be protective against IPD ﬁve years
after the administration of PCV7 are shown in Fig. 1. In
patients with CLL, these percentages varied from 29 to 71%,
with the lowest proportion found against serotype 4 and the
highest against serotypes 18C and 19F. In controls, the corre-
sponding percentages ranged 50- to 87.5%, with the lowest pro-
portion being against serotype 6B and the highest against
serotype 18C.
The baseline proportions of suggested protective antibody
concentrations before vaccination in patients with CLL ranged
8- to 88%. The lowest baseline proportion was against serotype
4 and the highest against serotype 19F. In controls, the same
percentages were 0–100%, with no protective concentrations
found against serotype 4. Protective antibody concentrations
against serotype 18C were observed in all controls before
vaccination.9
There is no earlier data available concerning pneumococ-
cal antibody persistence in patients with CLL. In HIV-
infected children on HAART, protective antibody concen-
trations of 0.5 mg/ml persisted for longer than four years
for serotypes 6B and 14 after PCV7-PCV7-PPV23 adminis-
tration.13 In adults of 50 years of age and older, antibody
concentrations declined over a ﬁve-year period following
the administration of PCV13 for all 13 serotypes but
remained higher than the levels before vaccination, except
for serotype 3.14 Furthermore, in 40% of allogeneic stem
cell transplant patients, who received three doses of PCV7
and one dose of PPV23 after transplantation, antibody con-
centrations remained at a protective level (0.50 mg/ml) for
8–11 years.15
In our data antibody concentrations in patients with CLL
declined during the ﬁve years following a single dose of
PCV7 for six serotypes and for all serotypes in healthy con-
trols. The number of subjects was quite small, but no statis-
tically signiﬁcant difference was seen between these two
groups in median antibody concentrations. There was, how-
ever, a trend toward lower antibody concentrations in CLL
patients compared to controls ﬁve years after PCV7 admin-
istration for all serotypes except for serotype 19F, which
was observed in higher concentrations in the patients. Cur-
rently recommended PCV13 contains six other serotypes (1,
3, 5, 6A, 7F, 19A), which are not included in PCV7. Anti-
body persistence in these additional serotypes remains still
unclear and warrants further studies.
More than half of the CLL patients remained their antibody
concentrations at protective levels for four out of seven sero-
types ﬁve years after PCV administration, although the median
antibody concentrations declined. Most of the patients had
Table 1. Clinical and laboratory characteristics of the patients with CLL.
Character Patients with CLL (N D 24)
Sex M/F 12/12
Age (years) 64 (47–86)
Binet A/B/C 16/2/6
Past or ongoing therapy 8 (33%)
Lymphocyte count (x109/l) 24.3 (0.9–140.0)
Platelet count (x109/l) 141 (38–372)
Hemoglobin (g/l) 135 (81–153)
Neutrophil count (x109/l) 4.0 (0.6–12.1)
IgG (g/l) 7.4 (3.2–12.5)
IgM (g/l) 0.3 (0.1–5.4)
IgA (g/l) 0.7 (0.2–4.5)
Table 2. Antibody concentrations against pneumococcal antigens of 7-valent conjugate vaccine four weeks and ﬁve years after vaccination in patients with CLL and in
controls.
Post-PCV antibody 5 yrs post-PCV antibody
level median (quartiles) level median (quartiles)
Serotype CLL Control CLL Control P-value1
4 0.30 (0.07–1.22) 1.87 (0.43–6.16) 0.15 (0.02–0.40) 0.52 (0.13–0.90) 0.116
6B 0.55 (0.20–1.82) 0.95 (0.23–14.7) 0.29 (0.09–0.94) 0.39 (0.06–1.24) 1.000
9V 1.40 (0.25–7.12) 18.0 (0.34–63.2) 0.33 (0.15–2.33) 0.97 (0.17–5.06) 0.685
14 0.72 (0.31–2.66) 14.7 (1.01–20.5) 0.73 (0.20–4.01) 2.71 (0.45–5.83) 0.676
18C 1.55 (0.81–5.99) 9.76 (4.65–81.1) 0.73 (0.23–3.06) 1.42 (1.00–2.47) 0.642
19F 2.01 (0.61–9.31) 3.26 (1.20–51.1) 1.07 (0.26–2.88) 0.69 (0.31–1.56) 1.000
23F 1.53 (0.66–13.4) 5.11 (0.98–23.0) 0.51 (0.17–1.56) 1.17 (0.11–2.23) 1.000
1Fishers exact test.
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never been treated for CLL, which may have some impact on
antibody persistence. Also, the relatively low rates of hypogam-
maglobulinemia and the low number of severe pneumococcal
infections may contribute to better persistence of protection.
Although the size of the study population was small, this fol-
low-up data reﬂects the trend of the antibody persistence ﬁve
years after PCV7 in patients with CLL.
Earlier data had shown a signiﬁcant increase in antibody
concentrations for all seven antigens in both groups after
PCV7 administration.9 In this follow-up study, the median
antibody concentrations in CLL patients at ﬁve years after
vaccination, as compared with the baseline levels before
vaccination, varied depending on the serotype. The post-
vaccination antibody concentrations for serotypes 4 and 14
were 1.6- and 1.3 –times higher than the baseline, respec-
tively. In contrast, for serotypes 6B and 18C, the median
antibody concentrations declined by almost 20% during the
ﬁve-year follow-up. Antibody concentrations for the other
three serotypes declined to baseline levels. Whether anti-
body concentrations continue to decline after ﬁve years of
follow-up remains unclear and warrants a longer follow-up
and further studies.
In our earlier data, serotypes 14 and 6B were the most
common serotypes causing IPD among patients with
hematological malignancy, including CLL. Our ﬁnding of
favorable persistence for serotype 14 emphasizes the impor-
tance of PCV administration for CLL patients in the early
stages of the disease, whereas the decline below baseline
seen for serotype 6B during the follow-up period may point
to a need for a booster dose of PCV or PSV ﬁve years after
the primary vaccination.
In conclusion, median antibody concentrations in
patients with CLL ﬁve years after PCV7 administration
varied depending on the serotype as compared to controls,
and there was a trend toward lower antibody concentrations
for six serotypes of PCV7. However, antibody concentra-
tions remained at a level considered to be protective against
IPD for four serotypes in more than 50% of the CLL
patients. Our ﬁndings suggest that PCV given at an early
stage of CLL could result in antibody persistence lasting at
least ﬁve years. The effectiveness and schedule of possible
booster immunization needs to be established in future
studies.
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ABSTRACT
The 23-valent pneumococcal polysaccharide vaccine (PPV23) given alone is ineffective in patients with
chronic lymphocytic leukemia (CLL) and better antibody response is achieved with pneumococcal
conjugate vaccines (PCVs). In this study, we determine whether CLL patients would achieve
a significant antibody response and broaden their serotype coverage against invasive pneumococcal
disease (IPD) with PPV23 given five years after the 7-valent conjugate vaccine (PCV7). A total of 24
patients with CLL and eight controls were vaccinated with PPV23 five years after PCV7. Blood samples
for evaluation of antibody response to PCV7 serotypes and PPV23 serotypes 5 and 7 were taken before
vaccination and one month after it. Post-vaccination samples were available from 20 patients. IgG
antibodies were measured with ELISA. Antibody concentrations after PPV23 were significantly lower in
CLL patients for six of the PCV7 serotypes and for both PPV23 serotypes. Only 10% to 15% of CLL
patients achieved an antibody response suggested to be protective against IPD. Hence, PCV7 given five
years before PPV23 did not improve antibody response in patients with CLL. Based on our results, PPV23
given after a PCV primer is not useful against IPD in CLL patients.
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Introduction
Infections are the most important cause of mortality in
patients with chronic lymphocytic leukemia (CLL), the most
common type of leukemia in adult Caucasians. The usual
bacterial pathogens responsible for respiratory tract and urin-
ary tract infections are Streptococcus pneumoniae,
Haemophilus influenzae, and Escherichia coli.1,2 CLL is asso-
ciated with an impaired immune system function even at an
early stage of the disease.3 Both the specific and innate immu-
nity are affected, leading to immunosuppression in patients
with CLL.4 Abnormalities in specific (adaptive) immunity
include B- and T-cell dysfunction while disorders of the
complement system and neutrophil functions represent
abnormalities in innate immunity.1,4–6 While hypogammaglo-
bulinemia can occur at an early stage of CLL, it is usually
more severe in the advanced stages of the disease.7 Low levels
of IgG have been observed to correlate with the severity of
bacterial infections, morbidity, and mortality.8
In contrast to the pneumococcal polysaccharide vaccine
(PPV), the T-cell dependent pneumococcal conjugate vaccines
(PCVs) have been shown to induce higher avidity antibodies
and immunologic memory and to create herd immunity.9
Antibody responses to pneumococcal vaccines in CLL patients
are limited. Most studies with 23-valent PPV (PPV23) have
shown no significant antibody responses.10–13 PCVs, in
contrast, have proved immunogenic in CLL patients with
limited response in a few earlier studies. In almost 40% of
CLL patients, a response, that was considered significant was
achieved after one dose of 7-valent PCV (PCV7) given at an
early stage of the disease.14 Furthermore, 13-valent PCV
(PCV13) resulted in at least a two-fold increase in antibody
titers from the baseline in 58% of untreated CLL patients,
compared with 100% for healthy controls.15 In a recent ran-
domized study, PCV13 was compared to PPV23 in untreated
CLL patients. Functional antibody titers measured by opso-
nophagocytic assay (OPA) were significantly higher for 11 out
of 13 serotypes with PCV13 at one month after vaccination
and for 6 out of 13 serotypes at six months after vaccination
compared to PPV23. All antibody responses for PPV23 were
inferior to achieved with PCV13.16
PPV23 given after PCV may have a booster effect on anti-
body responses and may also broaden serotype coverage to
PPV23 serotypes in immunocompromised patients. Patients
with previously treated Hodgkin lymphoma achieved higher
antibody concentrations for six serotypes contained in both
vaccines when PPV23 was given one year after PCV7 in
contrast to PPV23 alone.17 In stem cell transplant (SCT)
recipients, the antibody response rates to pneumococcal ser-
otypes 1 and 5 not included in PCV7 were 83% after one dose
of PPV23 at 12 months and 89% 18 months after 3 doses of
PCV7 with the cut-off of ≥0.15 μg/ml set for response.18
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Furthermore, 42% of allogeneic SCT recipients, who did not
show a response after three doses of PCV7 achieved an anti-
body response of ≥0.15 μg/ml to the PCV7 antigens after
a single dose of PPV23.19
In this study, we investigated the effect of a single dose of
PPV23 given five years after PCV7 to evaluate whether CLL
patients could obtain a boost to their antibody response and
broaden their serotype coverage against invasive pneumococ-
cal disease (IPD) with PPV23 primed with PCV7.
Patients and methods
The study population comprised 24 patients with CLL (12
males and 12 females), with a median age of 64 years (range
47–86 years) from Tampere and Turku University Hospitals.
The control population comprised eight subjects (median age
67 years, range 57–82 years, four males and four females)
without any known immunological or hematological defects
from Tampere University Hospital. The patients and control
subjects had participated in an earlier pneumococcal conju-
gate vaccine response study with PCV7 containing capsular
polysaccharides (PSs) of pneumococcal serotypes 4, 6B, 9V,
14, 18C, 19F and 23F, and in an antibody persistence
study.14,20
An informed consent to participate was obtained from all
patients and controls. The study was approved by the ethical
board of the Pirkanmaa Hospital District, and it was con-
ducted in accordance with the Declaration of Helsinki. The
trial was registered at http://ClinicalTrials.gov (NCT00919321).
The study objectives were to compare antibody concentra-
tions for PCV7 antigens and PPV23 antigens 5 and 7F, as an
example for antigens which are not included in PCV7, at one
month after vaccination in CLL patients and controls with
serotype-specific IgG antibodies as measured by ELISA and to
determine the proportions of CLL patients achieving
a significant serotype-specific antibody response against IPD
after PPV23.
The vaccine used was the 23-valent pneumococcal poly-
saccharide vaccine (Pneumovax®, MSD), which contains cap-
sular PSs of pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F,
23F, 33F. A dose of 0.5 ml contains 25 μg of each PS type and
phenol as an adjuvant.
Patients and controls received one intramuscular deltoid
injection with Pneumovax five years after PCV7. Venous
blood samples for antibody analyses were taken before vacci-
nation and one month after it. Serum was separated by cen-
trifugation and stored at −20°C. The concentrations of serum
IgG antibody against pneumococcal capsular PSs were mea-
sured at the National Institute for Health and Welfare (THL)
by a modification of the 22F inhibition enzyme immunoassay
(EIA) method as previously described.21 Additionally, venous
blood samples were drawn from CLL patients for the analysis
of total blood count and immunoglobulins at the time of
vaccination. These were analyzed at a local hospital.
Antibody concentrations and proportionate changes
between groups were compared by independent-samples
Mann–Whitney test and the significance of antibody
responses within groups by two-tailed Fisher´s exact test.
The values in the tables are expressed as geometric mean
concentrations (GMC) and quartiles. An antibody concentra-
tion of 0.35 μg/ml was considered as a threshold for protec-
tion against IPD, as recommended by the World Health
Organization WHO.22 A significant antibody response was
defined as an at least two-fold increase from the baseline
and a post-vaccination level of at least 0.35 μg/ml consistent
with earlier PCV7 study.14
Results
Among the 24 CLL patients and eight controls enrolled in the
study, post-vaccination samples were unavailable in the case
of four patients. Therefore, the final study population com-
prised of 20 CLL patients and eight controls (Table 1). No
vaccine-related adverse events were reported. The disease
status according to Binet classification was A (early stage of
the disease) in 12, B (intermediate) in two, and C (advanced
stage) in six patients. A total of 13 patients had never been
treated for CLL. After administration of PCV7, six patients
had received chemoimmunotherapy or chemotherapy, one
patient CD52 monoclonal antibody (alemtuzumab) after che-
motherapy and one patient had received allogeneic stem cell
transplantation. Hypogammaglobulinemia (S-IgG <6.77 g/l)
was detected in nine (45%) patients. Five patients had suffered
from severe infections (needing intravenous antibiotics or
hospitalization) and five patients from mild to moderate
infections (treated with oral antibiotics) during the five years
since PCV7 vaccination. Only one of these infections was an
invasive pneumococcal disease.
Antibody concentrations after PPV23 were significantly
higher in controls for four of PCV7 antigens (4, 9V, 14,
18C) and for both PPV23 antigens (Table 2). In contrast, no
difference was observed in antibody concentrations for PCV7
antigens 6B, 19F and 23F. Before PPV23, i.e., five years after
PCV7, no statistically significant differences were seen in
antibody concentrations between patients with CLL and
controls.20
After PPV23, only 10% to 15% of CLL patients achieved
a significant response to PCV7 antigens defined as an at least
two-fold increase and a post-vaccination concentration of at
least 0.35 μg/ml (Table 3). Among CLL patients, the responders
were the same four patients depending on the serotype, and
they had never been treated for CLL. These patients were also
among the PCV7 responders. For PPV23 antigens 5 and 7, the
corresponding percentages for CLL patients were 20% and 15%,
respectively. Despite poor antibody response, 30–75% of CLL
Table 1. Clinical and laboratory characteristics of the patients with CLL.
Character Patients with CLL (n = 20)
Sex M/F 11/9
Age (years) 63 (47–86)
Binet A/B/C 12/2/6
Past CLL therapy 7 (35%)
Lymphocyte count (x109/l) 21.9 (0.9–140.0)
Platelet count (x109/l) 141 (38–372)
Hemoglobin (g/l) 135 (81–153)
Neutrophil count (x109/l 4.0 (0.6–12.1)
IgG (g/l) 7.4 (3.2–12.5)
The values are expressed as medians and ranges.
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patients remained their antibody concentrations at a level ≥0.35
μg/ml suggested to be protective against IPD depending on
serotype. In controls, 75–88% achieved a significant response
to PCV7 antigens 4, 6B, 9V, 14, 18C, 19F. In contrast, the
corresponding rate for serotype 23F was only 50%. For PPV23
antigens, all controls achieved a significant response.
Discussion
According to a few earlier studies, patients with Hodgkin´s
lymphoma and SCT recipients benefit from a PCV primer
before PPV23.17–19 Furthermore, in HIV-infected adults,
PPV23 given one year after PCV13 improved PCV13
immunogenicity but in contrast, had a negative effect on
immunological memory induced by PCV13 by reducing the
amounts of memory B-cells.23 Similar findings have been
reported where PPV23 given after PCV depletes immuno-
logical memory. Longer intervals between pneumococcal
vaccinations diminish this hyporesponsiveness and are ben-
eficial for immunogenicity.24 Our study was designed based
on a long interval between vaccinations consistent with an
updated recommendation.25 However, we did not observe
this booster effect in CLL patients. Furthermore, a majority
of the untreated CLL patients did not achieve an antibody
response considered as significant for PPV23. Hence, in our
data CLL therapy after PCV7 did not seem to have an
influence on poor antibody responses for PPV23.
An antibody concentration of 1.3 μg/ml is recommended
as a cut-off for protective antibody level against IPD in pri-
mary immunodeficiencies.26 This higher cut-off level may also
be extrapolated to acquired immunodeficiencies, such as CLL
related immune dysfunction. In our data, all responders in
CLL group achieved this higher antibody concentration
expect two out of four CLL patients for antibody 5.
This is the first study to evaluate the effect of the 23-valent
polysaccharide vaccine after the conjugate vaccine (PCV7) in
patients with CLL. Although ≥50% of CLL patients remained
their antibody concentrations at a protective level for 7 out of 9
serotypes, most of the CLL patients did not achieve an antibody
response considered to be significant, as compared to controls.
These data suggest that PCV is not capable of inducing memory
B-cells in CLL patients, although our earlier data showed anti-
body persistence at least five years after PCV7, depending on the
serotype.26 One probable reason for a poor antibody response
with PPV23 after the PCV primer is abnormalities in both B-
and T – cell functions even at an early stage of CLL, leading to
inadequate immunogenicity of conjugate vaccines.1,4,15 Stage of
the disease in our data did not impair antibody responses as
most of the patients were Binet A patients.
Our study has some limitations. The sample size
remained small due to the natural course of CLL and the
five-year interval between vaccinations. PCV7 has also been
replaced with PCV13, but both have the same carrier pro-
tein, CRM.9 Furthermore, PCV13 has also been shown to
generate suboptimal responses in CLL patients.15,16 Hence,
our data should reflect immune responses to both PCV7
and PCV13.
A PPV23 booster dose given five years after PCV7 seemed
to be ineffective in inducing an antibody response suggested
to be protective against IPD in CLL patients. Based on these
data, PPV23 may not be useful as a part of the vaccination
program after PCVs in patients with CLL. Future studies with
the PCV13 primer are warranted in order to verify our data.
Furthermore, whether CLL patients would benefit from
a PCV13 booster instead of PPV23 needs to be studied.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Funding
This work was supported by the Helsinki University Hospital
Comprehensive Cancer Center.
Table 2. Pre- and post-vaccination antibody concentrations to seven serotypes
included in the 7-valent pneumococcal conjugate vaccine (PCV7, bold) and two
serotypes included in the 23-valent pneumococcal polysaccharide vaccine
(PPV23) in patients with CLL and in controls.
Pre-vaccination antibody
concentration GMC (μg/ml)
(quartiles)
Post-vaccination antibody
concentration GMC (μg/ml)
(quartiles)a
Serotype CLL (n = 20)
Control
(n = 8) CLL (n = 20)
Control
(n = 8) p-valuea
4 0.12
(0.02–0.40)
0.34
(0.13–0.90)
0.13
(0.02–0.67)
1.96
(1.36–2.82)
<0.001
5 0.16
(0.08–0.44)
0.15
(0.08–0.25)
0.22
(0.08–0.64)
2.20
(0.53–5.57)
0.002
6B 0.46
(0.11–1.69)
0.30
(0.06–1.24
0.56
(0.14–3.39)
2.28
(0.75–9.96)
0.063
7F 0.38
(0.07–1.27)
0.56
(0.31–1.23)
0.55
(0.07–1.83)
6.74
(2.97–13.8)
<0.001
9V 0.51
(0.23–2.33)
0.91
(0.17–5.06)
0.62
(0.32–2.29)
3.04
(0.58–12.1)
0.033
14 0.77
(0.20–4.14)
1.56
(0.45–5.83)
0.96
(0.17–6.20)
6.65
(3.00–24.0)
0.021
18C 0.93
(0.26–3.06)
1.55
(1.00–2.47)
1.06
(0.27–4.07)
6.81
(3.82–15.7)
0.010
19F 0.97
(0.30–2.88)
0.83
(0.31–1.56)
1.29
(0.33–4.20)
4.18
(1.88–6.05)
0.055
23F 0.53
(0.14–1.56)
0.82
(0.25–2.23
0.67
(0.13–4.41)
2.29
(2.07–3.32)
0.150
aBetween post-vaccination concentrations in patients with CLL and controls
aIndependent-samples Mann–Whitney U-test (statistical significance if p ≤ .05)
Table 3. Significant response rates and post-vaccination antibody concentra-
tions suggestive of protection (≥0.35 μg/ml) to seven serotypes included in
PCV7 (bold) and two serotypes included in PPV23 in patients with CLL and
controls.
Response ratea
Post-vaccination concentration
≥0.35 μg/ml
CLL Controls CLL Controls
Serotype n = 20 (%) n = 8 (%) p-valueb n = 20 (%) n = 8 (%
4 2 (10) 7 (88) <0.001 7 (35) 8 (100)
5 4 (20) 8 (100) <0.001 6 (30) 8 (100)
6B 2 (10) 6 (75) 0.002 10 (50) 7 (88)
7F 3 (15) 6 (75) <0.001 14 (70) 8 (100)
9V 3 (15) 7 (88) 0.001 13 (65) 8 (100)
14 2 (10) 7 (88) <0.001 12 (60) 8 (100)
18C 2 (10) 6 (75) 0.002 15 (75) 8 (100)
19F 3 (15) 7 (88) 0.001 15 (75) 8 (100)
23F 2 (10) 4 (50) 0.038 13 (65) 8 (100)
aDefined as an at least twofold increase and a post-vaccination concentration of
at least 0.35 μg/ml
bFisher´s exact test
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